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Abstract: Hsp90 is a molecular chaperone playing a pivotal role in 
the cell life cycle. ATP-regulated internal dynamics are critical for its 
function and we recently demonstrated that they can be modulated 
in an allosteric fashion, targeting the protein C-terminal domain 
(CTD) with a family of 2-phenyl-benzofuran derivatives. Here we 
describe the expansion of the initial library, reporting 28 new 
derivatives that explore the chemical space at opposite ends of the 
benzofuran scaffold. Interaction of the compounds with the full-
length protein was explored by Saturation Transfer Difference (STD) 
NMR. In this context we report also the interaction epitope of 
Novobiocin, a known CTD inhibitor.  
Introduction 
Heat shock proteins (HSPs) are a group of chaperone proteins 
overexpressed by cells under stress conditions. Among them, 
Hsp90 has been shown to play a central role in the maturation of 
numerous client proteins involved in several cancer hallmarks. 
As such, Hsp90 represents a hub in a signaling network that 
controls cell cycle and apoptosis and it is established as a target 
in cancer therapy. This chaperone exists as a homodimer, each 
protomer consisting of four regions: an N-terminal ATP binding 
domain, a middle domain that completes the catalytic site, a 
charged region, and a C-terminal homodimerization domain.[1]  A 
complex internal dynamics of the domains within the homodimer 
controls the chaperone activity of the protein and, with it, the 
downstream signalling pathways. This dynamic process is 
coupled to ATP hydrolysis and competitive inhibitors of ATP 
binding in Hsp90 N-terminal domain, such as geldanamycin or 
radicicol,[2] have shown potent antitumor activity in a wide-range 
of malignancies.[3] The amino-coumarin Novobiocin and its 
analogues[4] have been shown to bind the C-terminal domain 
(CTD) of Hsp90 and to lead to proteosomal degradation of the 
clients by inhibiting correct folding.  
Recently, small molecule activators of Hsp90 have been 
reported[5] and shown to act as allosteric modulators of ATPase 
activity. In particular, we have described a group of 
functionalized 2-(4-hydroxyphenyl)-3-methylbenzofurans (1, 
Figure 1) targeted against a computationally predicted allosteric 
site in Hsp90 and able to modify its enzymatic, conformational, 
co-chaperone and client-binding properties.[6] The best 
activators were shown to stimulate Hsp90 ATPase activity while 
simultaneously accelerating the rate of interprotomer closure 
dynamics, as revealed by FRET experiments. Some of these 
molecules were shown to affect the viability of cancer cell lines, 
including cells resistant to the geldanamycin derivative 17AAG, 
for which proper functioning of Hsp90 is required.[5b] In the 
absence of X-ray structures, Molecular Dynamics (MD) 
simulations guided the ligand selection process and were also 
used to reveal the mechanisms of Hsp90 modulation by the 
allosteric ligands.[7] An ensemble approach was adopted to 
characterize chaperone-ligand interactions, with the aim of 
identifying the hot spots of the allosteric site where key 
functional groups on the ligand best complement the receptor, 
while taking the dynamic exchange between the binding 
partners explicitly into account. This process led to the definition 
of two regions on the ligand where functional group 
diversification could arguably translate into a modulated 
response of the chaperone: the 5-substituent of the benzofuran 
ring (R1, Figure 1) and the phenol substituent (R2, Figure 1).  
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Figure 1. General structure of the 2-(4-hydroxyphenyl)-3-methylbenzofurans 
modulators 1. 
Here we describe the synthesis of 28 new derivatives in the 
active benzofuran series. These compounds were designed to 
expand the structure–activity relationship (SAR) observed in the 
initial generation for the R1 and R2 regions[7] and to explore the 
role played by specific structural features in determining 
compound potency. Hydrophilic and/or charged substituents 
were privileged, in an effort to increase the water solubility of the 
ligands. We also describe Saturation Transfer Difference (STD) 
NMR experiments with the yeast Hsp90 isoform, Hsc82, that 
confirm binding of the benzofuran ligands with the full protein. In 
this context, we present the first STD interaction study of 
Novobiocin with the same protein. STD data were combined to 
the MD-based characterization of the structures of 
Hsc82/allosteric ligand complexes.[6b] The results indicate 
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qualitative agreement between the two approaches, allowing to 
identify the ligand epitopes. 
Results and Discussion 
Diversification at R1 
 
The starting material for the group of benzofuran derivatives 
described so far is the 5-chloro-2-(4-hydroxyphenyl)-3-
methylbenzofuran 1a that we synthesized from 2-bromo-4-
chlorophenol by Pd-catalyzed enolate arylation, as previously 
described (Scheme 1).[8]  
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Scheme 1. Synthesis of 5-chloro-2-(4-hydroxyphenyl)-3-methyl-
benzofuran 1a by enolate arylation. (i) Pd(OAc)2, rac-2-(di-tert-
butylphosphino)-1,10-binaphthyl (rac-DTBPB), NaOtBu, toluene. (ii) TFA/DCM 
(iii) EtSNa, DMF 43% over the three steps (from[8]). 
The introduction of substituents other than chlorine at position 5 
required a different approach, based on a [3,3]-sigmatropic 
rearrangement of O-aryloximes described by Miyata et al[9], in 
the one-pot version introduced by Contiero (Scheme 2).[10] 
Condensation of an aryloxyamine 2 with ketone 3 yields the 
intermediate O-aryloxime 4, which is heated at 60 °C in THF and 
with an excess of MeSO3H to induce sigmatropic rearrangement 
of the protonated enamine isomer. Re-aromatization of the 
intermediate, followed by intramolecular cyclization and 
ammonia elimination afford the desired benzofuran 1 in 3-6 h 
and satisfactory yields (Scheme 2). 
Conversion of the 4-trifluoromethyl derivative 4d required 
harsher conditions and was achieved in 45% yield by replacing 
THF with higher boiling dioxane and performing the reaction at 
100 °C for 2 days. The starting aryloxyamines 2a-d were 
conveniently synthesized from N-hydroxyphthalimide 5 and the 
corresponding boronic acids 6a-d (Scheme 3) using a Cu-
mediated cross-coupling procedure developed by Petrassi et 
al.[11]  
It has already been shown that 1a is a suitable substrate for 
Stille coupling reaction with tributyl(1-propenyl)tin.[8] The 5-
bromo-2-(4-hydroxyphenyl)-3-methylbenzofuran 1b was 
instrumental to explore additional Pd catalyzed chemistry and to 
expand the library of 5-substituents. In particular, since 
calculations had suggested that the Hsp90 allosteric pocket may 
include complementary basic sites, a Heck[12] reaction was 
selected to introduce an acidic function to the benzofuran 
scaffold. Therefore, 1b and tBu acrylate were reacted in toluene 
affording the 5-substituted tBu ester 7 in 81% yields and 100% E 
selectivity (Scheme 4). Despite the acid sensitivity of the 
substrate, ester deprotection could be performed using 20% 
CF3COOH in CH2Cl2 to afford acid 8 in quantitative yields. 
Double bond reduction was also successfully achieved on a set 
of derivatives and will be described below. 
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Scheme 2. Synthesis of 5-substituted-2-(4-hydroxyphenyl)-3-methylbenzofurans 1a-d by [3,3]-sigmatropic of O-aryloximes 2a-d. 
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Scheme 3. Synthesis of the aryloxyamines 2a-d. (i) CuCl, 4 Å molecular 
sieves, 1,2-dichloroethane, air, room temperature, 48 – 72 h;  (ii) H2NNH2·H2O, 
10% MeOH in CH2Cl2; (iii) 4 M HCl in dioxane. 
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Scheme 4. Heck reaction of 1b (i) tBu acrylate, Pd(OAc)2, P(o-tol)3, TEA, 
toluene, reflux, 6h, 81%; (ii) 20% CF3COOH in DCM, 2h, quant. 
Diversification at R2 
 
Our initial set of data for R2 substituents had shown that basic 
groups at this position improve the activity of the benzofuran 
ligands as stimulators of Hsp90. Thus, we focused our attention 
on the introduction of amino groups in this region.  This was 
accomplished by phase transfer catalyzed (PTC) alkylation of 
the phenol oxygen of 1a, 1c and 7 with 2-chloro-N,N-
dimethylethylamine 9 or 3-chloro-N,N-dimethylpropylamine 10 
(Scheme 5) that allowed to obtain compounds 11-13 in good 
yields. The amino t-butylesters 14 and 18 (Scheme 5), obtained 
by alkylation of 7, were either directly deprotected (20% 
CF3COOH in CH2Cl2) to give the corresponding N,N-
dimethylamino acids 15 and 19, or hydrolyzed after reduction of 
the double bond (H2 and 10% Pd-C) to afford 17 and 21. 
In an effort to improve the solubility of the ligands, a second 
group of amine derivatives was prepared from epoxides 23 and 
24, synthesized by alkylation of 1a and 1b with epichlorohydrin 
22 (Scheme 6). Reaction of 23 with a set of four secondary 
amines in 9:1 CH2Cl2:EtOH mixture yielded compounds 25-28. 
Similarly, 32 was obtained by reaction of 24 with N-
methylpiperidine (Scheme 6). The primary amine 30 was 
prepared by NaN3 opening of 23 (dioxane, 80°C, cat. Yb(OTf)3, 
81% yield) and reduction of the resulting azide 29 under 
carefully controlled conditions (H2, PtO2, morpholine in MeOH, 
71% yield),[13] to avoid hydrogenolysis of the arylchloride. Finally, 
HCl-promoted hydrolysis of 23 in 3:1 dioxane:water mixture 
afforded the diol 31 in 60% yields (Scheme 6). 
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Scheme 5. PTC alkylation of the phenol with N,N-dimethylalkylamines. (i) 9·HCl, or 10·HCl, Bu4NHSO4, K2CO3, H2O 5% w/w୏మେ୓య , CHCl3; (ii) 20% 
CF3COOH in CH2Cl2; (iii) H2, Pd/C, MeOH, 2h, quant. 
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Scheme 6. Synthesis of epoxides 23 and 24 and nucleofilic opening reactions. (i) 22,  Bu4NHSO4, K2CO3, H2O 5% 5% w/w୏మେ୓య, CHCl3; (ii) for 25-28 and 
32: secondary amine, [9/1] CH2Cl2/EtOH; for 29: NaN3 in refluxing dioxane, Yb(OTf)3, 5 d, 81%; for 31: [3/1] dioxane/H2O, HCl, reflux, 5 h, 60%; (iii) H2, PtO2-
morpholine in MeOH, 71%. 
Two additional derivatives, 34 and 35 were prepared by 
activation of the known acid 33[5b] and reaction with morpholine 
or N-methylpiperazine, respectively (Scheme 7).  
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Scheme 7: Synthesis of amides 34 and 35. (i) EDC, morpholine, THF, 20 h, 
35%; (ii) a. Oxalyl chloride, b. N-Methylpiperazine, CH2Cl2, 78%. 
We have previously reported that a set of monoglycosides of 1a 
can modulate Hsp90 activity. In particular R2= -L-Rha, -D-
Man and -D-Gal were found to induce significant activation of 
Hsp90 ATPase.[5b] In order to harness the effect of both a sugar 
and an amino group, the synthesis of glycoconjugates of amino 
sugars was also attempted (Scheme 8). Glycosylation of 1a with 
6-azido-2,3,4-tri-O-benzoylmannose 1-trichloroacetimidate 36[14] 
occurred in good yields (62%) under standard  conditions 
(TMSOTf, -30°C) to afford the 6-azidomannoside 37 (Scheme 8). 
It is worth noting that, in the same conditions mannosylation of 
1a with 2,3,4,6-tetra-O-benzoylmannose 1-trichloroacetimidate 
afforded only a modest 20% yield[8].  Zemplén removal of the 
benzoyl esters occurred uneventfully to yield 38, which is barely 
soluble in MeOH. Reduction of the azido group could not be 
achieved, under a variety of conditions, mainly owing to poor 
solubility of 38 and of the resulting amine in most organic 
solvents.  
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Scheme 8. Glycosylation of 1a with 6-azidosugar donors. (i) 1a, TMSOTf, -30°C, 30 min, 62%; (ii) MeONa, MeOH; (iii) 1a, Bu4NHSO4, K2CO3, H2O 5% 
w/w୏మେ୓య, CHCl3, 40%. 
Hydrogenolysis with mild catalysts, such as Lindlar-Pd, left the 
starting material unreacted even after 1 day. Under more severe 
conditions, e.g. using Pd/C (AcOEt, 1% AcOH) or PtO2 and 
morpholine, several by-products (mostly from hydrogenolysis of 
the aryl-chloride bond) were observed by MS analysis, but none 
could be properly isolated. Similar results were obtained with the 
corresponding -glucoside 41, obtained by glycosylation of 1a 
with glucosylbromide 39[15] under PTC conditions. Zemplén 
removal of the acetyl groups from 40 occurred under unusually 
harsh conditions (MeOH, 40 °C, 2 d), due to the low solubility of 
the starting material in MeOH, and yielded the 6-azidoglucoside 
41 after precipitation from CH2Cl2. The compound was found to 
be soluble in acetone and could be fully characterized, but again 
we were unable to obtain clean reduction of the azido group. 
Glycosylation with other non-metabolic sugars was more 
successful. We focused on a limited group of commercially 
available monosaccharides, all characterized by the presence of 
an axial hydroxyl group either in position 2 or 4 of the pyranose 
ring, as suggested by the set of active glycosides identified in 
the previous campaign. The α-L-Man and the β-D-Fuc 
derivatives 42 and 43 (Table 1) are enantiomers of previously 
described derivatives[5b] and were synthesized accordingly. The 
L and D -arabinosides 44 and 45 were synthesized from the 
corresponding bromides, as exemplified in Scheme 9 for the L 
enantiomer. PTC alkylation of 1a with β-L-arabinopyranosyl 
bromide 2,3,4-triacetate 50[16] followed by Zemplén hydrolysis of 
the acetyl groups afforded L-arabinoside 44 (60% overall yield) 
exclusively in the α configuration (note: for pentapyranosides, 
the anomeric substituent is () if in trans (cis) relative to the 4-
hydroxy group[17]).  
The anomeric configuration of the compound could be 
established based on the 1,2 coupling constant of 7 Hz, typical 
of a 1,2-trans glycoside. Under the same conditions, 
glycosylation of 1a with the α-L-lyxopyranosyl bromide 2,3,4-
triacetate 51[18] (Scheme 9) afforded the desired product in less 
than 10% yield. Thus the O-benzoxazole (O-Box) donor 53 was 
prepared from bromide 52 and used under Demchenko’s 
conditions[19] to glycosylate 1a in overall 69% yields.  
Both anomers α-L-Lyx 54 and β-L-Lyx 55 were formed in this 
reaction in 56:44 ratio and were separated by flash 
chromatography (9:1 toluene/hexane). Their anomeric 
configuration and main conformation (shown in Scheme 9) were 
established by NMR experiments described in the Supporting 
Information. Benzoate removal afforded the final α-L-Lyx and β-
L-Lyx glycosides 46 and 47. The D-enantiomers 48 and 49 were 
obtained by the same route, starting from the D-enantiomer of 
lyxose. 
 
Table 1. Glycosylation of 1a with non-metabolic sugars 
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Scheme 9. Glycosylation of 1a with non-metabolic sugars. (i) 1a, Bu4NHSO4, K2CO3, H2O 5% w/w୏మେ୓య, CHCl3, 3 h, 83%; (ii) MeONa, MeOH; (iii) AgOBox, 
24%; (iv) 1a, TMSOTf, 1,2-dichloroethane, -78 °C, 69% combined yield (40% 54 and 29% 55). 
Interaction of the compounds with Hsp90: STD-NMR 
experiments 
 
While full characterization of the compounds activity on Hsp90 
ATPase and functional dynamics is in progress, we set out to 
characterize the interaction of selected library members with 
Hsp90 using NMR spectroscopy.  Saturation Transfer Difference 
(STD) NMR is one of the most widespread NMR methods to 
study the interaction between small molecules and 
macromolecular receptors.[20] The technique exploits the nuclear 
Overhauser effect and relies on the fast exchange equilibrium 
for a ligand between the free and bound state, in the presence of 
the receptor. Selective irradiation of the protein is followed by 
transfer of magnetization to the ligand protons, which in turn 
causes a partial saturation of the ligand signals, allowing to map 
the interaction epitope on the small molecule by analyzing the 
difference spectrum obtained in the absence or in the presence 
of the selective irradiation pulse. The ligand protons that are in 
closer contact with the protein receive a larger amount of 
magnetization transfer and give larger signals in the difference 
spectrum.   
To the best of our knowledge, no STD experiments have been 
reported with full-length Hsp90. Thus, to test the feasibility of this 
experiment, we first analyzed Novobiocin 56 (Figure 2A) in the 
presence of the yeast isoform of Hsp90, Hsc82. Novobiocin is 
the first and most studied inhibitor of the Hsp90 carboxy 
terminus.[21] To date, no co-crystal structure of Hsp90 bound to 
C-terminal ligands has been solved, so that information on the 
size and nature of the binding pocket and on ligands positioning 
is based exclusively on computational SAR and molecular 
docking studies.[22] Novobiocin affinity for Hsp90 was estimated 
to be in the millimolar range by SPR and other techniques,[23] 
which makes it ideally suitable for STD analysis. However, NMR 
interaction experiments have never been reported, so far.  
 
 
 
Figure 2. STD-NMR experiments with Novobiocin 56. (a) Formula of Novobiocin 56. (b) 1H-NMR spectrum of 56 in presence of Hsc82 in a 200:1 
Ligand/Protein ratio. (c) STD spectrum of 56 in presence of Hsc82 in a 200:1 L/P ratio. STD was obtained by irradiating the protein at -0.05 ppm with total 
saturation times of 0.98 s. The water suppression was achieved by Watergate 3-9-19 pulse sequence. The relative STD values, grouped in four intensity ranges, 
are marked with different colours and point up that the prenylated hydroxylphenyl ring is making the closest contacts with the protein in the bound state. 
The STD spectrum of Novobiocin 56 in the presence of Hsc82 
was obtained in deuterated phosphate buffer with a 200:1 
ligand:protein ratio, using as irradiating frequency the upfield 
aliphatic region of the protein. The spectrum is reported in 
Figure 2C, together with the 1H spectrum of Novobiocin 56 in the 
same conditions (Figure 2B). The molecule appears to be 
deeply embedded in the protein binding site since different 
degrees of magnetization transfer could be observed for each 
proton (Figure 2C). A quantitative analysis of these data (Figure 
2 and Supporting Information) suggests that the interaction 
epitope of Novobiocin strongly involves the prenylated phenol 
ring, the coumarin moiety and, to a lesser extent, the noviose 
ring. These observations are consistent with the results of MD-
based studies of Hsc82/Novobiocin complexes.[6b] In the latter, 
extensive MD simulation of 56 docked to the putative allosteric 
pocket were run and characterized by means of cluster analysis. 
The representative structure (Figures 3b, right panel) was 
largely consistent with STD, showing the prenyl, aromatic and 
sugar protons at contact distance with the protein. Additionally, 
the OCH3 substituent at noviose 4’ position was also calculated 
to point towards the interior of the protein, as consistent with the 
observed STD signal.  
 
Figure 3. Hsp90 complexes of benzofuran 11 (a) and Novobiocin 56 (b). Dynamic equilibrium between open and closed Hsp90 is differentially affected by 11 
(a, left panel) and Novobiocin (b, left panel) resulting in activation and inhibition of the ATPase activity, respectively. The docked complexes of Hsc82 with 11 (a) 
and Novobiocin (b) are shown in the right panels.  
NMR analysis of the benzofuran derivatives in the presence of 
Hsc82 was severely impaired by the low solubility of the 
compounds in water. Finally, conditions were established 
whereby compound 11 (Figure 4A) could be dissolved in the 
aqueous buffer at the appropriate concentration and maintained 
in solution after addition of the protein. The amine 11 has 
already been characterised as a powerful Hsp90 allosteric 
activator.[5b] The predicted binding site (Figure 3a) is close to the 
region occupied by Novobiocin (Figure 3b). However, MD 
simulations suggest that formation of the Hsp90:Novobiocin 
complex blocks the protein in a partially inactive state (Fig 3b, 
left panel), whereas interaction with 11 results in higher 
frequency turnover of the closed-active state (Fig. 3a, left panel) 
and allosterically stimulates ATPase activity.  
STD NMR experiments were recorded with a 200:1 
ligand:protein ratio at different saturation times, using as 
irradiating frequency the upfield methyl region of the protein. A 
selected spectrum is reported in Figure 4C and the 
corresponding 1D spectrum is shown in Figure 4B.  
The results confirmed that binding occurs between compound 
11 and Hsc82 and that the recognition is strongly mediated by 
aromatic protons (belonging both to the phenol and benzofuran 
rings). An intense STD signal was also observed for N-CH2 and 
N-methyl groups. In particular, the protons of the aromatic rings 
show the largest saturation transfer and the N-CH3 group the 
lowest effect, suggesting that the region of the ligand comprising 
the aromatic rings is making the closest contacts with the protein 
binding site. A competition experiment between 11 and 
Novobiocin was attempted, but it was frustrated by precipitation 
of the ligand. In good agreement with STD, the representative 
structures from MD simulations of the Hsc82/11 complex (Figure 
3a, right panel) show extensive packing of the benzofuran and 
aromatic rings of the ligand with the protein, coupled to contacts 
involving both the N-CH2 and N-methyl groups of the amine 
modification.[7] Within the limitations of MD sampling for such 
large and complex systems, and with a caveat on the qualitative 
nature of the comparison, comparative analysis of STD and MD 
results provides a consistent structural model for the complexes 
in solution. It is worth noting, moreover, that such knowledge 
has been used to guide the development of more potent 
derivatives, providing further support to the validity of the model.
 Figure 4. STD-NMR experiments with benzofuran derivative 11.  (a) 
Formula of 11. (b) 1H-NMR spectrum of 11 in presence of Hsc82 in a 200:1 
Ligand/Protein ratio. (c) STD spectrum of 11 in presence of Hsc82 in a 200:1 
L/P ratio. STD was obtained by irradiating the protein at -0.05 ppm with total 
saturation times of 2.94s. The water suppression was achieved by Watergate 
3-9-19 pulse sequence. The relative STD values are grouped in four intensity 
ranges and marked with different colors. 
Conclusions 
A library of Hsp90 stimulators characterized by a 2-(4-
hydroxyphenyl)-3-methylbenzofuran structure has been 
significantly expanded. Groups at position 5 of the benzofuran 
ring were diversified using a [3,3]-sigmatropic rearrangement of 
O-aryloximes for the synthesis of the benzofuran core and a 
Heck cross-coupling reaction for further modifications. The 
synthesis of a second set of compounds, diversified at position 
R2 was achieved by alkylation of the phenol ring followed by 
further elaborations. Glycosylation of 1a with amino sugars was 
attempted but abandoned due to low solubility of the products, 
while other non-metabolic sugars could be successfully 
introduced. Overall, 28 new compounds were synthesized, 
demonstrating the versatility of the benzofuran platform.  STD-
NMR analysis of the interaction of the known allosteric 
modulator 11 with the yeast isoform of Hsp90 (Hsc82) proved 
that the ligand actually binds to the protein and confirmed the 
role of the benzofuran scaffold in establishing the interaction. 
The spectra showed that also the substituents of the amino 
group are in close contact with the protein, providing a viable 
structural model that can be used to guide the development of 
more potent derivatives. Full characterization of the 28 new 
compounds activity on Hsp90 ATPase and functional dynamics 
is underway. 
Experimental Section 
Protein expression and purification: The Hsc82 cloned into pET28b 
(Novagen, U.S.) and transformed into BL21 (DE3) cells (NEB, U.S.). The 
protein expression was induced by 0.5 mM IPTG (Goldbio, U.S.) at 20 °C 
for 16 hours. The cells were lysed using EmulsiFlex-C3 (Avestin, 
Canada). The lysate was purified using Ni-NTA column (Qiagen, U.S.), 
monoQ ion exchange chromatography (GE, U.S.) and Superdex200 gel 
filtration chromatography (GE. U.S.). 
STD-NMR: All NMR spectra were recorded on a Bruker Avance 
spectrometer operating at 600 MHz. All data were collected at 298 K. 1D, 
COSY, and NOESY (mixing time of 200 and 700 ms) were recorded 
using standard sequences from Bruker library, on Novobiocin 56 (0.23 
mg, MW=634.6, 2 mM) and Compound 11 (0.3 mg, MW=366.3, 4.5 mM) 
in order to assign all the resonances. The sample was prepared in 
deuterated 20 mM PBS buffer. Data were analysed using Bruker Topspin 
software. After NMR characterization, 30 µL of the Hsc82 solution (10 
mg/mL, MW=80899.7) was added to each sample, giving to a 200:1 L/P 
ratio.  For the acquisition of NMR Saturation Transfer Difference (STD) 
experiments, a 1D-pulse sequence incorporating a T1ρ filter to remove 
disturbing protein signals was used.  The STD spectra were performed 
with an on-resonance irradiation frequence at −0.05 ppm, while 200 ppm 
was chosen as off-resonance frequence. Selective presaturation of the 
protein was achieved by a train of Gauss shaped pulses, each of 49 ms 
in length. STD experiments were acquired on each sample varying the 
total saturation times from 0.49 to 3.92 s (with 0,49s increments). In STD 
experiments, water suppression was achieved by using the 
WATERGATE 3-9-19 pulse sequence. For both product blank 
experiments in absence of protein were performed. 
Synthesis – general: Dry dichloromethane (DCM), methanol, 1,4-
dioxane and triethylamine (TEA) were distilled over calcium hydride; 
tetrahydrofuran (THF) was distilled over sodium. Dichloroethane (DCE) 
was dried over 4 Å molecular sieves and hexane (Hex) and toluene were 
used as purchased. Reactions requiring anhydrous conditions were 
performed under nitrogen, or argon where indicated. AgOBox was 
synthesized as reported.[19] 1H and 13C spectra were recorded at 400 
MHz or 100 MHz, respectively, on a Bruker AVANCE-400 instrument. 
Chemical shifts (δ) for 1H and 13C spectra are expressed in ppm relative 
to internal standard (CDCl3: 7.26 for 1H and 77.16 for 13C; CD3OD: 3.31 
for 1H and 49.00 for 13C; (CD3)2CO: 2.05 for 1H and 29.84 for 13C). 
Signals were abbreviated as s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; b means broad as in bs, broad singlet. Quaternary carbon 
signals were abbreviated as Cq. All assignments were confirmed with the 
aid of two-dimensional 1H-1H (COSY), 1H-13C (HSQC) and/or 1H-13C 
(HMBC) experiments using standard pulse programs. Processing of the 
spectra was performed using TopSpin or MestReNova software. Sugar 
signals were numbered as customary; benzofuran signals were 
numbered as customary and indicated with the suffix Bf, and the 
substituents of benzofuran do not have any numbering, but they are 
clearly indicated in the characterizations; OBox signals were numbered 
as customary and indicated with the suffix Box. In the names of the 
compounds the conventional numbering is used. Mass spectra were 
obtained with a ThermoFisher LCQ apparatus (ESI ionization), or iontrap 
ESI Esquire 6000 from Bruker, or Apex II ICR FTMS (ESI ionization—
HR-MS). Thin layer chromatography (TLC) was carried out with pre-
coated Merck F254 silica gel plates. Flash chromatography (FC) was 
carried out with Macherey-Nagel silica gel 60 (230–400 mesh), according 
to Still’s procedure.[24] Automated chromatography was performed using 
a BiotageIsolera Prime. Compounds 1a, 11, 12, 33,[5b] 1b,[9] 39[15] and 
50[16] have been described previously. Glycosides 42 and 43 were 
characterized based on the spectral data reported for their enantiomers[8] 
and on the sign of their optical rotation. Boronic acids 57a-d and ketone 3 
are commercially available. 
General procedure I. Synthesis of the 5-substituted-2-(4-
hydroxyphenyl)-3-methyl-benzofurans (1a-c):[10] The phenyloxyamine 
hydrochloride 2a-c (1 mmol) was suspended in THF (3 mL) under 
nitrogen. Freshly activated, acid washed 4 Å molecular sieves (0.1 g) and 
1-(4-hydroxyphenyl)propan-1-one 3 (1 mmol) were added. The solution 
was stirred for 5 min at 60 °C, then methanesulfonic acid (2 mmol) was 
added. The mixture was stirred for 5 h and the progress was followed by 
HP-TLC (8:2 Toluene:DCM, each sample was diluted with DCM and 
quenched with NaHCO3 before deposition on TLC).The reaction mixture 
was then diluted with EtOAc, the organic phase was washed with 
NaHCO3 (2x5 mL), and brine (2x5 mL), dried over anhydrous Na2SO4 
and concentrated in vacuo. The crude was purified by chromatography 
as described below. 
5-chloro-2-(4-hydroxyphenyl)-3-methylbenzofuran (1a): General 
procedure I performed starting from 2a. The crude was purified by flash 
chromatography (Toluene:DCM gradient from 10% to 25% DCM) leading 
in 51% yield to product 1a, whose spectral data corresponded with those 
reported in the literature[8]. 1H-NMR (400 MHz, CDCl3): δ = 7.67 (d, Jo-m = 
8.8 Hz, 2 H, 2 x H-m-Phe-O), 7.45 (d, J4-6 = 2 Hz, 1 H, H-4Bf), 7.35 (d, J7-
6 = 8.6 Hz, 1 H, H-7Bf), 7.20 (dd, 1 H, H-6Bf), 6.96 (d, 2 H, 2 x H-o-Phe-
O), 2.39 (s, 3 H, CH3-Bf) ppm. 
5-bromo-2-(4-hydroxyphenyl)-3-methylbenzofuran (1b): General 
procedure I performed starting from 2b. The crude was purified using an 
automated chromatography system (SiO2, Hex:EtOAc gradient from 30% 
to 100% EtOAc), to afford compound 1b in 70% yield as a white solid, 
whose spectral data corresponded with those reported in the literature.[9] 
1H-NMR (400 MHz, CDCl3): δ = 7.68 (d, Jo-m = 8.3 Hz, 2 H, 2 x H-m-Phe-
O), 7.62 (s, 1 H, H-4Bf), 7.38-7.29 (m, 2 H, H-6Bf, H-7Bf), 6.95 (d, 2 H, 2 
x H-o-Phe-O), 2.40 (s, 3 H, CH3Bf) ppm. 
5-fluoro-2-(4-hydroxyphenyl)-3-methylbenzofuran (1c): General 
procedure I performed starting from 2c. The crude was purified by flash 
chromatography (8:2 Hex:EtOAc, Rf=0.3) leading to product 1c in 56% 
yield. 1H-NMR (400 MHz, CDCl3): δ = 7.68 (d, Jo-m = 8.9 Hz, 2 H, 2 x H-
m-Phe-O), 7.37 (dd, J7-6 = 8.9 Hz,4JHF = 4.2 Hz, 1 H, H-7Bf), 7.15 (dd, J4-6 
= 2.6 Hz, 3JH-F = 8.6 Hz, 1 H, H-4Bf), 7.00-6.93 (m, 3 H, H-6Bf, 2 x H-o-
Phe-O), 5.22 (bs, 1 H, OH), 2.39 (s, 3 H, CH3-Bf) ppm. 13C-NMR (100 
MHz, CDCl3): δ = 160.5 (Cq), 156.9 (d, 1JCF= 240 Hz, C-F), 155.7 (Cq), 
152.7 (Cq), 149.9 (Cq), 132.3 (d, 3JCF= 10 Hz, Cq), 128.6 (2 x C-m-Ph-O), 
124.2 (Cq), 115.8 (2 x C-o-Ph-O), 111.6 (d, 2JCF= 12 Hz, C-6Bf), 111.4 (d, 
3JCF= 4.4 Hz, C-7Bf), 110.1 (Cq), 104.8 (d, 2JCF= 30 Hz, C-4Bf), 9.5 (CH3-
Bf) ppm. ESI-MS: calcd for C15H10O2F [M-H]- 241.2, found 241.0 
5-trifluoromethyl-2-(4-hydroxyphenyl)-3-methylbenzofuran (1d): 
Phenyloxyamine hydrochloride 2d (1 mmol) was suspended in dioxane 
(3 mL) under nitrogen. Freshly activated, acid-washed 4 Å molecular 
sieves (0.1 g) and 1-(4-hydroxyphenyl)propan-1-one 3 (1 mmol) were 
added. The solution was stirred for 5 min at 40 °C, then methanesulfonic 
acid (2 mmol) was added and the mixture was stirred for 2 days at 
100 °C. The reaction progress was followed by RP-HPLC (C18, 
H2O:CH3CN gradient from 30% to 100% CH3CN; retention time of 1d 
1.36 min; retention time of the oxime intermediate 4d 1.38 min; each 
sample was diluted with DCM and quenched with NaHCO3 before 
injection). The reaction mixture was diluted with EtOAc, the organic 
phase was washed with NaHCO3 (2x5 mL), and brine (2x5 mL), dried 
over anhydrous Na2SO4 and concentrated in vacuo. The crude was 
purified by flash chromatography (8:2 Hex:EtOAc, Rf=0.4) leading to 
product 1c in 45% yield. 1H-NMR (400 MHz, CDCl3): δ = 7.79 (bs, 1 H, 
H-4Bf), 7.71 (d, Jo-m = 8.8 Hz, 2 H, 2 x H-m-Phe-O), 7.55-7.48 (m, 2 H, H-
7Bf, H-6Bf), 6.97 (d, 2 H, 2 x H-o-Phe-O), 5.07 (bs, 1 H, OH), 2.46 (s, 3 H, 
CH3-Bf) ppm. 13C-NMR (100 MHz, CDCl3): δ = 155.9 (Cq), 154.0 (q, 
1JCF= 241 Hz , CF3), 131.5 (Cq), 128.7 (2 x C-m-Ph-O), 125.1 (q, 2JCF= 32 
Hz, CCF3), 123.8 (Cq), 121.1 (q, 3JCF= 3.7 Hz, C-6Bf), 116.8 (q, 3JCF= 4.1 
Hz, C-4Bf), 115.9 (2 x C-o-Ph-O), 111.2 (C-7Bf), 110.0 (Cq), 9.4 (CH3-Bf) 
ppm. ESI-MS: calcd for C16H10F3O2 [M-H]- 291.064, found 291.092. 
E-t-butyl 3-(2-(4-hydroxyphenyl)-3-methylbenzofuran-5-yl)acrylate 
(7):[12] Compound 1b (131 mg, 0.43 mmol), Pd(OAc)2 (1 mg, 0.043 
mmol) and (o-tol)3P (5 mg, 0.017 mmol) were dissolved in toluene (800 
μL) under nitrogen atmosphere. TEA (300 μL, 0.73 mmol) and tBu-
acrylate (76 μL, 0.52 mmol) were added. The mixture was warmed to 
reflux for 6 h (TLC 8:2 Hex:EtOAc). The reaction was cooled to room 
temperature and diluted with EtOAc. The mixture was washed with 1 M 
HCl (2x5 mL), water (2x5 mL) and brine (1x5 mL), dried over anhydrous 
Na2SO4 and concentrated in vacuo. The crude was purified using an 
automated chromatography system (SiO2, Hex:EtOAc gradient from 30% 
to 100% EtOAc) to afford compound 7 (122 mg, 81% yield, 100% E 
selectivity) as a white solid. 1H-NMR (400 MHz, CDCl3): δ = 7.71 (m, 3 H, 
2 x H-m-Phe-O, =CH-Ar), 7.64 (s, 1 H, H-4Bf), 7.44 (s, 2 H, H-6Bf, H-7Bf), 
6.96 (d, Jo-m = 8.7 Hz, 2 H, 2 x H-o-Phe-O), 6.39 (d, Jtrans = 15.9 Hz, 1 H, 
=CH-C=O), 2.44 (s, 3 H, CH3Bf), 1.56 (s, 9 H, 3 x CH3-tBu) ppm. 13C-NMR 
(100 MHz, CDCl3): δ = 166.9 (C=O), 155.9 (Cq-phenol), 154.9 (Cq-Bf), 
152.1 (Cq-Bf), 144.5 (=CH-Ar), 132.0 (Cq-Bf), 129.5 (Cq-phenol), 128.6 (2 
x C-m-Ph-O), 124.3 (C-6Bf), 124.0 (Cq-Bf), 119.2 (C-4Bf), 118.7 (=CH-
C=O), 115.8 (2 x C-o-Ph-O), 111.3 (C-7Bf), 109.9 (Cq-Bf), 80.6 (Cq-tBu), 
28.4 (3 x CH3-tBu), 9.5 (CH3-Bf) ppm. ESI-MS: calcd for C22H22NaO4 
[M+Na]+ 373.1416, found 373.1462. 
General procedure II - Phenol alkylation: synthesis of 13, 14, 18, 23 
and 24: The benzofuran (1a-c or 7; 0.3 mmol) and the alkylating agent (9 
or 10 or 22; 1 mmol) were dissolved in CHCl3 (3 mL). Water (19 μL), 
K2CO3 (2.7 mmol) and the phase transfer catalyst (Bu4NHSO4, 0.15 
mmol) were added and the mixture was kept overnight at 45°C under 
vigorous stirring. When the reaction was complete (TLC 95:5 
CHCl3:MeOH) it was diluted with chloroform and brine, the aqueous 
phase was extracted with chloroform (2x10 mL) and the organic phases 
were washed with water (2x20 mL), dried over Na2SO4 and concentrated 
in vacuo.  
5-fluoro-2-(4-(2-(dimethylamino)ethoxy)phenyl)-3-methylbenzofuran 
(13): Prepared from 1c and 9, following the general procedure II. The 
crude was purified by flash chromatography (CHCl3 + 1%TEA, Rf=0.26) 
leading to product 13 in 81% yield. 1H-NMR (400 MHz, 9:1 
CD3OD:CDCl3): δ = 7.73 (d, Jo-m = 8.8 Hz, 2 H, 2 x H-m-Phe-O), 7.40 (dd, 
J6-7 = 8.9 Hz, 4JHF  = 4.0 Hz, 1 H, H-7Bf), 7.21 (dd, J4-6 = 2.6 Hz, 3JHF = 8.8 
Hz, 1 H, H-4Bf), 7.08 (d, 2 H, 2 x H-o-Phe-O), 7.04-6.94 (m, 1 H, H-6Bf), 
4.19 (t, Jgem = Jvic = 5.3 Hz, 2 H, CH2-O), 2.96-2.86 (m, 2 H, CH2-N), 2.45 
(bs, 6 H, 2xCH3-N), 2.40 (s, 3 H, CH3Bf) ppm. 13C-NMR (100 MHz, 9:1 
CD3OD:CDCl3): δ = 161.8 (Cq), 160.6 (d, 1JCF = 238 Hz, C-F), 160.0 (Cq), 
153.9 (Cq), 151.1 (Cq), 129.2 (2 x C-m-Ph-O), 125.2 (Cq), 115.8 (2 x C-o-
Ph-O), 112.3 (d, 3JCF = 5.3 Hz, C-7Bf), 112.2 (d, 2JCF= 11.4 Hz, C-6Bf), 
105.5 (C-4Bf, 2JCF= 25 Hz), 66.2 (CH2-O), 58.8 (CH2-N), 45.6 (NMe2), 9.4 
(CH3-Bf) ppm. ESI-MS: calcd for C19H20FNNaO2 [M+Na]+ 336.3, found 
336.0 
E-t-butyl-3-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-3-
methylbenzofuran-5-yl)acrylate (14): Prepared from 7 and 9, following 
the general procedure II for phenol alkylation. The crude was purified 
using an automated chromatography system (SiO2, 
CHCl3:MeOH:TEA (1%) gradient from 0 to 20% MeOH) to afford the 
product as a white foam (50% yield). 1H-NMR (400 MHz, CDCl3): δ = 
7.75-7.69 (m, 3 H, =CH-Ar, 2 x H-m-Phe-O), 7.65 (br s, 1 H, H-4Bf), 7.44 
(br s, 2 H, H-6Bf, H-7Bf), 7.04 (d, Jo-m = 8.9 Hz, 2 H, 2 x H-o-Phe-O), 
6.39 (d, Jtrans = 15.9 Hz, 1 H, =CH-C=O), 4.13 (t, JCH2-CH2 = 5.7 Hz, 2 H, 
CH2-O), 2.77 (t, 2 H, CH2-N), 2.44 (s, 3 H, CH3Bf), 2.36 (s, 6 H, NMe2), 
1.55 (s, 9 H, 3xCH3-tBu) ppm. 13C-NMR (100 MHz, CDCl3): δ = 166.8 
(C=O), 158.8 (Cq-phenol), 154.8 (Cq-Bf), 152.1 (Cq-Bf), 144.4 (=CH-Ar), 
132.0 (Cq-Bf), 129.4 (Cq-phenol), 128.3 (2 x C-m-Ph-O), 124.2 (C-6Bf), 
124.0 (Cq-Bf), 119.1 (C-4Bf), 118.7 (=CH-C=O), 115.0 (2 x C-o-Ph-O), 
111.3 (C-7Bf), 109.9 (Cq-Bf), 80.4 (Cq-tBu), 66.0 (CH2-O), 58.3 (CH2-N), 
45.9 (NMe2), 28.4 (3 x CH3-tBu), 9.5 (CH3-Bf) ppm. ESI-MS:calcd for 
C26H32NO4 [M+H]+ 422.2331, found 422.2418. 
E-t-butyl-3-(2-(4-(3-(dimethylamino)propoxy)phenyl)-3-
methylbenzofuran-5-yl)acrylate (18): Prepared from 7 and 10, following 
the general procedure II for phenol alkylation. The crude was purified 
using an automated chromatography system (SiO2, 
CHCl3:MeOH:TEA (1%) gradient from 0 to 20% MeOH) to afford the 
product in 62% yield as a white foam. 1H-NMR (400 MHz, CDCl3): δ = 
7.75-7.68 (m, 3 H, =CH-Ar, 2 x H-m-Phe-O), 7.64 (s, 1 H, H-4Bf), 7.43 (br 
s, 2 H, H-6Bf, H-7Bf), 7.00 (d, Jo-m = 8.8 Hz, 2 H, 2 x H-o-Phe-O), 6.39 (d, 
Jtrans = 15.9 Hz, 1 H, =CH-C=O), 4.09 (t, JCH2-CH2 = 6.2 Hz, 2 H, CH2-O), 
2.62 (t, 2 H, CH2-N), 2.44 (s, 3 H, CH3Bf), 2.38 (s, 6 H, NMe2), 2.12-2.02 
(m, 2 H, CH2-CH2-CH2), 1.55 (s, 9 H, 3 x CH3-tBu) ppm. 13C-NMR (100 
MHz, CDCl3): δ = 166.8 (C=O), 158.9 (Cq-phenol), 154.9 (Cq-Bf), 152.1 
(Cq-Bf), 144.4 (=CH-Ar), 132.0 (Cq-Bf), 129.4 (Cq-phenol), 128.3 (2 x C-
m-Ph-O), 124.3 (C-6Bf), 124.0 (Cq-Bf), 119.2 (C-4Bf), 118.7 (=CH-C=O), 
114.8 (2 x C-o-Ph-O), 111.3 (C-7Bf), 109.9 (Cq-Bf), 80.5 (Cq-tBu), 65.9 
(CH2-O), 56.3 (CH2-N), 44.8 (NMe2), 28.4 (3 x CH3-tBu), 26.7 (CH2-CH2-
CH2), 9.5 (CH3-Bf) ppm. ESI-MS: calcd for C27H34NO4 [M+H]+ 436.2488, 
found 436.3021. 
5-chloro-3-methyl-2-(4-(oxiran-2-ylmethoxy)phenyl)benzofuran (23): 
Obtained in quantitative yield by reaction of 1a and epichlorohydrin 22, 
following the general procedure II for phenol alkylation. TLC: 6:4 
Hex:DCM, Rf=0.3. No purification required. 1H-NMR (400 MHz, CDCl3): δ 
= 7.72 (d, Jo-m = 8.6 Hz, 2 H, 2 x H-m-Phe-O), 7.46 (s, 1 H, H-4Bf), 7.36 
(d, J7-6 = 8.6 Hz, 1 H, H-7Bf), 7.21 (d, 1 H, H-6Bf), 7.03 (d, 2 H, 2 x H-o-
Phe-O), 4.30 (dd, Jgem = 11.0 Hz, Jvic  = 3.0 Hz, 1 H, CH2-OAr), 4.02 (dd, 
Jvic = 5.7 Hz, 1 H, CH2-OAr), 3.43-3.37 (m, 1 H, CH-O), 2.94 (t, Jgem = 4.9 
Hz, Jvic = 4.5 Hz, 1 H, CH2-O), 2.79 (dd, Jvic = 2.8 Hz, 1 H, CH2-O), 2.40 
(s, 3 H, CH3Bf) ppm. 13C-NMR (100 MHz, CDCl3): δ = 158.6 (Cq-phenol), 
152.3 (Cq-Bf), 151.1 (Cq-Bf), 132.9 (Cq), 128.4 (2 x C-m-Ph-O), 128.1(Cq), 
124.3 (Cq), 124.1 (C-6Bf), 118.9 (C-4Bf), 115.0 (2 x C-o-Ph-O), 111.9 (C-
7Bf), 109.7 (Cq), 69.0 (CH2-OAr), 50.2 (CH-O), 44.8 (CH2-O), 9.5 (CH3Bf) 
ppm. ESI-MS: calculated for C18H15ClNaO3 [M+Na]+ 337.0, found 337.0 
5-bromo-3-methyl-2-(4-(oxiran-2-ylmethoxy)phenyl)benzofuran (24): 
Prepared by reaction of 1b and epichlorohydrin 22, following the general 
procedure II for phenol alkylation. TLC: 6:4 Hex:DCM, Rf=0.4.The crude 
was purified by flash chromatography (85:15 toluene:DCM, Rf=0.3) and 
the product was isolated  in 75% yield. 1H-NMR (400 MHz, CDCl3): δ = 
7.71 (d, J = 9.0 Hz, 2 H, 2 x H-m-Phe-O), 7.61 (d, J4-6 = 1.8 Hz, 1 H, H-
4Bf), 7.34 (dd, J7-6 = 8.6 Hz, J4-6 = 1.8 Hz, 2 H, H-6Bf), 7.31 (d, 1 H, H7-
Bf), 7.02 (d, 2 H, 2 x H-o-Phe-O), 4.29 (dd, Jgem = 11.0 Hz, Jvic = 3.0 Hz, 1 
H, CH2-OAr), 4.00 (dd, Jvic = 5.9 Hz, 1 H, CH2-OAr), 3.42-3.37 (m, 1 H, 
CH-O), 2.94 (dd, Jgem = 4.7, Jvic = 4.3 Hz, 1 H, CH2-O), 2.79 (dd, Jvic = 3.2 
Hz, 1 H, CH2-O), 2.41 (s, 3 H, CH3Bf) ppm. 13C-NMR (100 MHz, CDCl3): 
δ = 158.5 (Cq), 152.4 (Cq), 152.0 (Cq), 133.4 (Cq), 128.3 (2 x C-m-Ph-O), 
126.7 (C-6Bf), 124.1 (Cq), 121.8 (C-4Bf), 115.4 (Cq), 114.9 (2 x C-o-Ph-
O), 112.3 (C-7Bf), 109.4 (Cq), 68.8 (CH2-OAr), 50.1 (CH-O), 44.7 (CH2-
O), 9.4 (CH3Bf) ppm. ESI-MS: calcd for C18H15BrO3 [M+H]+ 360.2, 
found 360.4 
Double bond reduction. Synthesis of 16 and 20: To a solution of E-t-
butylacrylate (14 or 18, 0.1 mmol) in MeOH (1 mL), Pd/C was added. The 
mixture was stirred for 2 h at room temperature under H2 atmosphere. 
The crude was filtered through celite to remove the catalyst and the 
filtrate concentrated in vacuo to afford the product (16 or 20, respectively) 
as a white foam. 
t-butyl 3-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-3-methyl 
benzofuran-5-yl)propanoate (16): Obtained from 14 in 94% yield. 1H-
NMR (400 MHz, CDCl3): δ = 7.72 (d, Jo-m = 8.9 Hz, 2 H, 2 x H-m-Phe-O), 
7.35 (d, J7-6 = 8.3 Hz, 1 H, H-7Bf), 7.32 (d, J4-6 = 1.6 Hz, 1 H, H-4Bf), 7.10 
(dd, 1 H, H-6Bf), 7.02 (d, J = 8.9 Hz, 2 H, 2 x H-o-Phe-O), 4.13 (t, JCH2-
CH2 = 5.7 Hz, 2 H, CH2-O), 3.02 (t, JCH2-CH2 = 7.8 Hz, 2 H, CH2-Ar), 2.77 (t, 
2 H, CH2-N), 2.59 (t, 2 H, CH2-C=O), 2.42 (s, 3 H, CH3Bf), 2.37 (s, 6 H, 
NMe2), 1.43 (s, 9 H, tBu) ppm. 13C-NMR (100 MHz, CDCl3): δ = 172.4 
(C=O), 156.6 (Cq-phenol), 152.4 (Cq-Bf), 150.5 (Cq-Bf), 135.0 (Cq-Bf), 
131.3 (Cq-phenol), 128.3 (2 x C-m-Ph-O), 124.7 (C-6Bf), 118.5 (C-4Bf), 
114.8 (2 x C-o-Ph-O), 110.6 (C-7Bf), 110.3 (Cq-Bf), 80.3 (Cq-tBu), 63.0 
(CH2-O), 56.7 (CH2-N), 46.0 (NMe2), 43.93, 37.9 (CH2-C=O), 31.2 (CH2-
Ar), 28.1 (CH3-tBu), 9.4 (CH3-Bf) ppm. ESI-MS: calcd for C26H34NO4 
[M+H]+ 424.2488, found 424.2982. 
t-butyl 3-(2-(4-(3-(dimethylamino)propoxy)phenyl)-3-methyl 
benzofuran-5-yl)propanoate (20): Obtained from 18 in 82% yield. 1H-
NMR (400 MHz, CDCl3): δ = 7.71 (d, Jo-m = 8.8 Hz, 2 H, 2 x H-m-Phe-O), 
7.38-7.30 (m, 2 H, H-4Bf, H-7Bf), 7.10 (dd, J6-7 = 8.3 Hz, J6-4 = 1.5 Hz, 1 
H, H-6Bf), 6.98 (d, 2 H, 2 x H-o-Phe-O), 4.09 (t, JCH2-CH2 = 6.1 Hz, 2 H, 
CH2-O), 3.02 (t, JCH2-CH2 = 7.8 Hz, 2 H, CH2-Ar), 2.83-2.77 (t, 2 H, CH2-N), 
2.59 (t, 2 H, CH2-C=O), 2.51 (s, 6 H, NMe2), 2.41 (s, 3 H, CH3Bf), 2.18-
2.08 (m, 2 H, CH2-CH2-CH2), 1.43 (s, 9 H, tBu) ppm. 13C-NMR (100 MHz, 
CDCl3): δ = 172.6 (C=O), 158.4 (Cq-phenol), 152.6 (Cq-Bf), 151.1 (Cq-Bf), 
135.0 (Cq-Bf), 131.5 (Cq-phenol), 128.3 (2 x C-m-Ph-O), 124.6 (C-6Bf), 
118.6 (C-4Bf), 114.7 (2 x C-o-Ph-O), 110.6 (C-7Bf), 109.8 (Cq-Bf), 102 
(Cq-Bf), 80.5 (Cq-tBu), 65.7 (CH2-O), 56.2 (CH2-N), 44.5 (NMe2), 38.0 
(CH2-C=O), 31.4 (CH2-Ar), 29.84, 28.2 (CH3-tBu), 26.2 (CH2-CH2-CH2), 
9.5 (CH3-Bf) ppm. ESI-MS: calcd for C27H36NO4 [M+H]+ 438.3, found 
438.4 
Hydrolysis of t-butyl esters. Synthesis of 8, 15, 17, 19, 21: To a DCM 
solution (1.8 mL) of the t-butyl ester (7, 14, 16, 18 or 20; 0.1 mmol) under 
a flux of nitrogen, TFA (400 μL) was added dropwise. The reaction was 
stirred for 2 h then concentrated in vacuo. TFA was co-evaporated with 
toluene to afford pure product (quantitative yield) without any further 
purification. 
E-3-(2-(4-hydroxyphenyl)-3-methylbenzofuran-5-yl)acrylic acid (8): 
1H-NMR (400 MHz, CD3OD): δ = 7.82 (d, Jtrans = 16.0 Hz, 1 H, =CH-Ar), 
7.78 (d, 1 H, H-4Bf), 7.66 (d, Jo-m = 8.8 Hz, 2 H, 2 x H-m-Phe-O), 7.55 
(dd, J6-7 = 8.5 Hz, J6-4 = 1.6 Hz, 1 H, H-6Bf), 7.47 (d, 1 H, H-7Bf), 6.92 (d, 
2 H, 2 x H-o-Phe-O), 6.52 (d, 1 H, =CH-C=O), 2.45 (s, 3 H, CH3Bf) ppm. 
13C-NMR (100 MHz, CD3OD): δ = 176.1 (C=O), 159.0 (Cq-phenol), 156.2 
(Cq-Bf), 153.8 (Cq-Bf), 146.9 (=CH-Ar), 133.3 (Cq-Bf), 131.0 (=CH-
COOH), 130.6 (Cq-phenol), 129.4 (2 x C-m-Ph-O), 125.2 (C-6Bf), 123.6 
(Cq-Bf), 120.4 (C-4Bf), 116.6 (2 x C-o-Ph-O), 112.0 (C-7Bf), 110.3 (Cq-Bf), 
9.3 (CH3-Bf) ppm. HRMS (ESI): calcd for C18H13O4 [M-H]- 293.08193, 
found 293.08172. 
E-3-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-3-methylbenzofuran-5-
yl)acrylic  acid (15): Isolated as the trifluoroacetate salt after t-Bu ester 
removal from 14. 1H-NMR (400 MHz, CD3OD): δ = 7.84-7.76 (m, 4 H, 
=CH-Ar, 2 x H-m-Phe-O, H-4Bf), 7.56 (dd, J6-7 = 8.5, J6-4 = 1.5 Hz, 1 H, 
H-6Bf), 7.47 (d, 1 H, H-7Bf), 7.17 (d, Jo-m = 8.9 Hz, 2 H, 2 x H-o-Phe-O), 
6.49 (d, Jtrans = 16.0 Hz, 1 H, =CH-C=O), 4.46-4.41 (m, 2 H, CH2-O), 
3.67-3.61 (m, 2 H, CH2-N), 3.02 (s, 6 H, NMe2), 2.46 (s, 3 H , CH3Bf) 
ppm. 13C-NMR (100 MHz, CD3OD): δ = 170.7 (C=O), 159.1 (Cq-phenol), 
156.2 (Cq-Bf), 152.9 (Cq-Bf), 147.0 (=CH-Ar), 133.1 (Cq-Bf), 130.7 (Cq-
phenol), 129.4 (2 x C-m-Ph-O), 126.1 (Cq-Bf), 125.6 (C-6Bf), 120.7 (C-
4Bf), 117.8 (=CH-C=O), 116.0 (2 x C-o-Ph-O), 112.2 (C-7Bf), 111.5 (Cq-
Bf), 63.2 (CH2-O), 57.7 (CH2-N), 43.9 (NMe2), 9.3 (CH3-Bf) ppm. HRMS 
(ESI): calcd for C22H24NO4+[M+H]+366.16998, found 366.17028. 
3-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-3-methylbenzofuran-5-
yl)propanoic acid (17): Isolated as the trifluoroacetate salt after t-Bu 
ester removal from 16. 1H-NMR (400 MHz, CD3OD): δ = 7.74 (d, Jo-m = 
8.9 Hz, 2 H, 2 x H-m-Phe-O), 7.37 (d, J4-6 = 1.1 Hz, 1 H, H-4Bf), 7.33 (d, 
J7-6 = 8.4 Hz, 1 H, H-7Bf), 7.15-7.10 (m, 3 H, 2 x H-o-Phe-O, H-6Bf), 
4.40-4.36 (m, 2 H, CH2-O), 3.64-3.58 (m, 2 H, CH2-N), 3.03-2.97 (m, 8 H, 
CH2-Ar, NMe2), 2.64 (t, JCH2-CH2 = 7.7 Hz, 2 H, CH2-C=O), 2.39 (s, 3 H, 
CH3Bf) ppm. 13C-NMR (100 MHz, CD3OD): δ = 176.8 (C=O), 158.8 (Cq-
phenol), 153.8 (Cq-Bf), 151.9 (Cq-Bf), 136.4 (Cq-Bf), 132.6 (Cq-phenol), 
129.2 (2 x C-m-Ph-O), 126.6 (Cq-Bf), 125.8 (C-6Bf), 119.5 (C-4Bf), 115.9 
(2 x C-o-Ph-O), 111.4 (C-7Bf), 111.2 (Cq-Bf), 63.2 (CH2-O), 57.7 (CH2-N), 
43.9 (NMe2), 37.4 (CH2-C=O), 32.1 (CH2-Ar), 9.40 (CH3-Bf) ppm. HRMS 
(ESI): calcd for C22H26NO4+ [M+H]+ 368.18563, found 368.18594. 
E-3-(2-(4-(3-(dimethylamino)propoxy)phenyl)-3-methylbenzofuran-5-
yl)acrylic acid (19): Isolated as the trifluoroacetate salt after t-Bu ester 
removal from 18. 1H-NMR (400 MHz, CD3OD): δ = 7.83-7.71 (m, 4 H, 
=CH-Ar, 2 x H-m-Phe-O, H-4Bf), 7.55 (dd, J6-7 = 8.6, J6-4 = 1.5 Hz, 1 H, 
H-6Bf), 7.46 (d, 1 H, H-7Bf), 7.08 (d, Jo-m = 8.9 Hz, 2 H, 2 x H-o-Phe-O), 
6.49 (d, J = 15.9 Hz, 1 H, =CH-C=O), 4.18 (t, JCH2-CH2 = 5.7 Hz, 2 H, CH2-
O), 3.39 (t, 2 H, CH2-N), 2.96 (s, 6 H, NMe2), 2.44 (s, 3 H, CH3Bf), 2.31-
2.19 (m, 2 H, CH2-CH2-CH2) ppm. 13C-NMR (100 MHz, CD3OD): δ = 
170.7 (C=O), 159.9 (Cq-phenol), 156.2 (Cq-Bf), 153.1 (Cq-Bf), 147.1 
(=CH-Ar), 133.2 (Cq-Bf), 130.6 (Cq-phenol), 129.2 (2 x C-m-Ph-O), 125.4 
(C-6Bf), 125.4 (Cq-Bf), 120.6 (C-4Bf), 117.7 (=CH-C=O), 115.8 (2 x C-o-
Ph-O), 112.1 (C-7Bf), 111.1 (Cq-Bf), 66.0 (CH2-O), 56.8 (CH2-N), 43.6 
(NMe2), 25.7 (CH2-CH2-CH2), 9.3 (CH3-Bf) ppm. HRMS (ESI): calcd for 
C23H28NO4+ [M+H]+ 382.20128, found 382.20177. 
3-(2-(4-(3-(dimethylamino)propoxy)phenyl)-3-methylbenzofuran-5-
yl)propanoic acid (21): Isolated as the trifluoroacetate salt after t-Bu 
ester removal from 20. 1H-NMR (400 MHz, CD3OD): δ = 7.75 (d, Jo-m = 
8.9 Hz, 2 H, 2 x H-m-Phe-O), 7.40 (d, 1 H, H-4Bf), 7.35 (d, 1 H, H-7Bf), 
7.15 (dd, J6-7 = 8.4, J6-4 = 1.7 Hz, 1 H, H-6Bf), 7.09 (d, 2 H, 2 x H-o-Phe-
O), 4.19 (t, JCH2-CH2 = 5.7 Hz, 2 H, CH2-O), 3.39 (t, JCH2-CH2 = 8.0 Hz, 2 H, 
CH2-N), 3.03 (t, JCH2-CH2 = 7.6 Hz, 2 H, CH2-Ar), 2.96 (s, 6 H, NMe2), 2.66 
(t, 2 H, CH2-C=O), 2.42 (s, 3H, CH3Bf), 2.31-2.21 (m, 2 H, CH2-CH2-CH2) 
ppm. 13C-NMR (100 MHz, CD3OD): δ = 177.0 (C=O), 159.6 (Cq-phenol), 
153.8 (Cq-Bf), 152.1 (Cq-Bf), 136.4 (Cq-Bf), 132.6 (Cq-phenol), 129.1 (2 x 
C-m-Ph-O), 125.9 (Cq-Bf), 125.7 (C-6Bf), 119.5 (C-4Bf), 115.8 (2 x C-o-
Ph-O), 111.3 (C-7Bf), 110.9 (Cq-Bf), 66.0 (CH2-O), 56.8 (CH2-N), 43.7 
(NMe2), 37.5 (CH2-C=O), 32.1 (CH2-Ar), 25.7 (CH2-CH2-CH2), 9.4 (CH3-
Bf) ppm. HRMS (ESI): calcd for C22H26NO4+[M+H]+382.20128, found 
382.20177. 
4-[5-chloro-3-methylbenzofuran-2-yl]-phenoxy-2-hydroxy-3-
dimethylamino propane (25): Dimethylamine (33% in EtOH, 0.1 mL, 
0.56 mmol) was added to a solution of epoxide 23 (39.2 mg, 0.125 mmol) 
in anhydrous ethanol (2 mL) and the reaction was stirred at 80 °C for 1 h 
(TLC 6:4 Hex:EtOAc and 9:1 CHCl3:MeOH+ 1% TEA). The solvent and 
the excess of amine were evaporated at reduced pressure obtaining the 
crude product (44 mg) that was purified by flash chromatography (9:1 
CHCl3:MeOH + 1% TEA). The desired product 25 was obtained as a 
white solid in 82 % yield (36.7 mg). 1H-NMR (400 MHz, CDCl3): δ = 7.71 
(d, Jo-m = 8.9 Hz, 2 H, 2 x H-m-Phe-O), 7.45 (d, J4-6 = 2.1 Hz, 1 H, H4-Bf), 
7.36 (d, J7-6 = 8.6 Hz, 1 H, H7-Bf), 7.20 (dd, 1 H, H6-Bf), 7.03 (d, 2 H, 2 x 
H-o-Phe-O), 4.11 (m, 1 H, CHOH), 4.04 (d, Jvic = 4.9 Hz, 2 H, CH2O), 
2.59 (dd, Jgem = 12.2 Hz, Jvic = 9.9 Hz, 1 H, CH2N), 2.43 (dd, Jvic = 3.6 Hz, 
1 H, CH2N), 2.40 (s, 3 H, CH3-Bf), 2.36 (s, 6 H, NMe2) ppm. 13C-NMR 
(100 MHz, CDCl3): δ = 158.9 (Cq), 152.4 (Cq), 152.1 (Cq), 132.9 (Cq), 
128.3 (C-m-Ph-O), 128.0 (Cq), 124.1 (C6-Bf), 124.0 (Cq), 118.8 (C4-Bf), 
114.9 (C-o-Ph-O), 111.8 (C7-Bf), 109.5 (Cq), 70.6 (CH2O), 66.2 (CHOH), 
61.9 (CH2N), 45.7 (NMe2), 9.5 (CH3-Bf) ppm. MS (ESI+): Calculated for 
C20H22ClNO3 [M+H]+360.1,Found 360.3 
1-(4-(5-chloro-3-methylbenzofuran-2-yl)phenoxy)-3-(N-
methylpiperazyl) propan-2-ol (26): To a solution of the epoxide 23 (0.1 
mmol) in dry EtOH (1 mL) 1-methylpiperazine (0.5 mmol) was added. 
The reaction was stirred for 2 h at 80 °C, monitoring by TLC (7:3 
Toluene:EtOAc and 9:1 CHCl3:MeOH). The solvent was evaporated 
under vacuum and the crude purified by flash chromatography (8:2 
CHCl3:MeOH) to afford 26 in 58% yield. 1H-NMR (400 MHz, CDCl3): δ = 
7.72 (d, Jo-m = 8.9 Hz, 2 H, 2 x H-m-Phe-O), 7.46 (d, J4-6 = 2.0 Hz, 1 H, 
H4-Bf), 7.36 (d, J7-6 = 8.6 Hz, 1 H, H7-Bf), 7.21 (dd, 1 H, H6-Bf), 7.03 (d, 
2 H, 2 x H-o-Phe-O), 4.15 (m, 1 H, CHOH), 4.05 (d, Jvic = 4.9 Hz, 2 H, 
CH2O), 2.81-2.56 (m, 10 H, CH2N), 2.40 (s, 3 H, CH3-Bf), 2.37 (s, 3 H, 
NMe) ppm. 13C-NMR (100 MHz, CDCl3): δ = 158.9 (Cq), 152.1 (Cq), 
132.9 (Cq), 128.4 (C-m-Ph-O), 128.1 (Cq), 124.1 (C6-Bf), 118.9 (C4-Bf), 
114.9 (C-o-Ph-O), 111.9 (C7-Bf), 109.6 (Cq), 70.4 (CH2O), 65.6 (CHOH), 
60.5 (CH2NCH2CH2NMe), 55.0 (CH2NCH2CH2NMe), 45.8 (NCH3), 9.5 
(CH3-Bf) ppm. MS (ESI+): Calculated for C23H28ClN2O3 [M+H]+ 415.2, 
Found 415.5. 
1-(4-(5-chloro-3-methylbenzofuran-2-yl)phenoxy)-3-
(cyclopropylamino) propan-2-ol (27): The epoxide 23 (20 mg, 63 µmol) 
was suspended in a solution of DCM/EtOH (0.6 mL, 9:1 ratio). 
Cyclopropylamine (13 µL, 0.19 mmol) was added to the reaction mixture. 
The reaction was stirred for 24 h at 40 °C. The reaction was followed by 
TLC chromatography (9:1:0.1 DCM:MeOH:TEA, Rf=0.47). The solution 
was concentrated in vacuo. The crude was purified by flash 
chromatography (96:4 CHCl3:MeOH) leading to product 27 (13 mg, 23 
µmol) in 60% yield. 1H-NMR (400 MHz, CD3OD): δ = 7.76 (d, Jo-m = 8.5 
Hz, 2 H, 2 x H-m-Phe-O), 7.53 (d, J4-6 = 2 Hz, 1 H, H-4Bf), 7.41 (d, J7-6 = 
8.5 Hz, 2 H, H-7Bf), 7.23 (dd, 1 H, H-6Bf), 7.12 (d, 2 H, 2 x H-o-Phe-O), 
4.36-4.29 (m, 1 H, CH-O), 4.15-4.06 (m, 2 H, CH2-O), 3.88 (bs, 1 H, NH), 
3.43 (dd, Jgem = 12 Hz, Jvic = 2 Hz, 1 H, CH2-N), 3.30-3.25 (m, 1 H, CH2-
N), 2.85-2.78 (m, 1 H, CH-N), 2.41 (s, 3 H, CH3-Bf), 1.00-0.91 (m, 4 H, 
CH2-cycle) ppm. 13C-NMR (100 MHz, CD3OD): δ = 160.0 (Cq), 153.5 (Cq), 
153.3 (Cq), 134.0 (Cq), 129.3 (2 x C-m-Ph-O), 129.1 (Cq), 125.3 (Cq), 
125.1 (C-6Bf), 119.7 (C-4Bf), 115.9 (2 x C-o-Ph-O), 112.7 (C-7Bf), 110.7 
(Cq), 71.0 (CH2-O), 66.3 (CH-O), 51.9 (CH2-N), 31.5 (CH-N), 9.3 (CH3-Bf), 
4.3 (CH2-cycle), 4.0 (CH2-cycle) ppm. ESI-MS: calcd for C23H27ClNO3 
[M+H]+ 372.9, found 372.8. 
1-(4-(5-chloro-3-methylbenzofuran-2-yl)phenoxy)-3-
(cyclopentylamino) propan-2-ol (28): Obtained from 23 and 
cyclopentylamine with the same procedure described above for 27. The 
reaction was followed by TLC chromatography (6:4 Hex:EtOAc, Rf = 0.1). 
The solution was concentrated in vacuo. The crude was purified by flash 
chromatography (97:3 CHCl3:MeOH, Rf=0.3) leading to product 28 (24 
mg, 59 µmol) in 93% yield. 1H-NMR (400 MHz, 9:1 CD3OD:1,4-dioxane-
d8): δ = 7.73 (d, Jo-m = 8.8 Hz, 2 H, 2 x H-m-Phe-O), 7.50 (d, J4-6 = 2 Hz, 
1 H, H-4Bf), 7.40 (d, J7-6 = 8.8 Hz, 2 H, H-7Bf), 7.21 (dd, 1 H, H-6Bf), 7.10 
(d, 2 H, 2 x H-o-Phe-O), 4.34-4.26 (m, 1 H, CH-O), 4.14-4.05 (m, 2 H, 
CH2-O), 3.69-3.55 (m, 1 H, CH-N), 3.36-3.28 (m, 1 H, CH2-N), 3.21-3.12 
(m, 1 H, CH2-N), 2.37 (s, 3 H, CH3-Bf), 2.22-2.10 (m, 2 H, CH2-cycle), 
1.89-1.78 (m, 2 H, CH2-cycle), 1.62 (m, 4 H, CH2-cycle) ppm. 13C-NMR 
(100 MHz, 9:1 CD3OD:1,4-dioxane-d8): δ = 160.2 (Cq), 153.6 (Cq), 153.5 
(Cq), 134.2 (Cq), 129.4 (2 x C-m-Ph-O), 129.3 (Cq), 125.4 (Cq), 125.2 (C-
6Bf), 119.9 (C-4Bf), 116.1 (2 x C-o-Ph-O), 112.9 (C-7Bf), 110.8 (Cq), 71.2 
(CH2-O), 67.0 (CH-O), 61.0 (CH-N), 50.6 (CH2-N), 30.8 (CH2-cycle), 30.7 
(CH2-cycle), 25.2 (CH2-cycle), 9.5 (CH3-Bf) ppm. ESI-MS: calcd for 
C23H27ClNO3 [M+H]+ 400.9, found 400.2 
1-azido-3-(4-(5-chloro-3-methylbenzofuran-2-yl)phenoxy)propan-2-ol 
(29): Epoxide 23 (39 mg, 0.12 mmol) was dissolved in 1,4-dioxane (0.7 
mL). A solution of NaN3 (24 mg, 0.37 mmol) and Yb(OTf)3 (15,5 mg, 36 
µmol) in H2O (0.18 mL) was added and the solution was stirred for 5 
days at 80 °C. The reaction was followed by TLC (7:3 Hex:EtOAc, 
Rf=0.39). The reaction mixture was diluted with EtOAc, washed once with 
H2O and once with brine. The organic layer was dried over Na2SO4 and 
concentrated in vacuum. The crude was purified by flash 
chromatography (55:45 toluene:DCM, Rf=0.3) leading to product 29 
(34 mg, 97 µmol) in 81% yield. 1H-NMR (400 MHz, CDCl3): δ = 7.73 (d, 
Jo-m = 8.8 Hz, 2 H, 2 x H-m-Phe-O), 7.47 (d, J4-6 = 2 Hz, 1 H, H-4Bf), 7.37 
(d, J7-6 = 8.8 Hz, 2 H, H-7Bf), 7.21 (dd, 1 H, H-6Bf), 7.03 (d, 2 H, H-o-
Phe-O), 4.26-4.18 (m, 1 H, CH-O), 4.08 (d, Jvic = 5 Hz, 2 H, CH2-O), 3.60 
(dd, Jgem = 12.7 Hz, Jvic = 4.7 Hz, 1 H, CH2-N3), 3.54 (dd, Jgem = 12.7 Hz, 
Jvic = 6.0 Hz, 1 H, CH2-N3), 2.41 (s, 3 H, CH3-Bf) ppm. 13C-NMR (100 
MHz, CDCl3): δ = 158.3 (Cq), 132.8 (Cq), 128.4 (2 x C-m-Ph-O), 128.1 
(Cq), 124.6 (Cq), 124.2 (C-6Bf), 118.9 (C-4Bf), 114.9 (2 x C-o-Ph-O), 
111.9 (C-7Bf), 109.8 (Cq), 69.4 (CH-O), 69.3 (CH2-O), 53.5 (CH2-N3), 9.5 
(CH3-Bf) ppm. ESI-MS: calcd for C18H17ClN3O3 [M+H]+ 358.8, found 
358.4 
1-amino-3-(4-(5-chloro-3-methylbenzofuran-2-yl)phenoxy)propan-2-
ol (30): Azide 29 (20 mg, 56 µmol) was dissolved in MeOH (0.46 mL). 
Morpholine (1.3 µL, 15 µmol) and PtO2 (1.3 mg, 2 µmol) were added to 
the solution. The reaction mixture was stirred for 1 h under H2 
atmosphere; the reaction progress was followed by TLC (8:2:0.2 
CHCl3:MeOH:AcOH, Rf=0.49). The reaction mixture was filtered on a 
celite pad and concentrated in vacuum. The crude was purified by flash 
chromatography (75:25:0.2 CHCl3:MeOH:AcOH, Rf=0.35) leading to 
product 30 (13 mg, 40 µmol) in 71% yield. 1H-NMR (400 MHz, CD3OD): δ 
= 7.71 (d, Jo-m = 8.8 Hz, 2 H, 2 x H-m-Phe-O), 7.50 (d, J4-6 = 2 Hz, 1 H, H-
4Bf), 7.39 (d, J7-6 = 8.8 Hz, 2 H, H-7Bf), 7.20 (dd, 1 H, H-6Bf), 7.08 (d, 2 
H, H-o-Phe-O), 4.06-4.00 (m, 2 H, CH2-O), 3.99-3.92 (m, 1 H, CH-O), 
2.96-2.84 (m, 1 H, CH2-NH2), 2.84-2.72 (m, 1 H, CH2-NH2), 2.38 (s, 3 H, 
CH3-Bf) ppm. 13C-NMR (100 MHz, CD3OD): δ = 160.5 (Cq), 153.7 (Cq), 
153.4 (Cq), 134.1 (Cq), 129.3 (2 x C-m-Ph-O), 129.1 (Cq), 125.0 (C-6Bf), 
125.0 (Cq), 119.7 (C-4Bf), 115.9 (2 x C-o-Ph-O), 112.7 (C-7Bf), 110.5 
(Cq), 71.6 (CH-O), 71.4 (CH2-O), 45.1 (CH2-NH2), 9.3 (Cp, CH3-Bf) ppm. 
ESI-MS: calcd for C18H19ClNO3 [M+H]+ 332.1, found 332.0 
3-(4-(5-chloro-3-methylbenzofuran-2-yl)phenoxy)propan-1,2-diol 
(31): Epoxide 23 (20 mg, 0.064 mmol) was dissolved in 1,4-dioxane (0.3 
mL). H2O (75 µL) and 4 M solution of HCl in dioxane (32 µL) were added 
to the reaction mixture. The reaction was stirred for 5 h at 80 °C and its 
progress was followed by TLC chromatography (7:3 Hex:EtOAc, Rf=0.4). 
NaOH was added until pH=7 was reached. The reaction mixture was 
diluted with EtOAc and washed with H2O. The water layer was extracted 
with EtOAc three times. The organic layer was dried over Na2SO4 and 
concentrated in vacuum. The crude was purified by flash 
chromatography (8:2 Hex:EtOAc, Rf=0.28) leading to product 31 (6 mg, 
38 µmol) in 60% yield. 1H-NMR (400 MHz, CD3OD): δ = 7.73 (d, Jo-m = 
8.9 Hz, 2 H, 2 x H-m-Phe-O), 7.51 (d, J4-6 = 2 Hz, 1 H, H-4Bf), 7.40 (d, J7-
6 = 8.8 Hz, 2 H, H-7Bf), 7.22 (dd, 1 H, H-6Bf), 7.09 (d, 2 H, 2 x H-o-Phe-
O), 4.13 (dd, Jgem = 9.3 Hz, Jvic = 3.9 Hz, 1 H, CH2-O), 4.06-3.97 (m, 3 H, 
CH2-O, CH-O), 3.71 (dd, Jgem = 11.2 Hz, Jvic = 5.3 Hz, 1 H, CH2-OH), 3.67 
(dd, Jvic = 5.3 Hz, 1 H, CH2-OH), (s, 3 H, CH3-Bf) ppm. 13C-NMR (100 
MHz, CD3OD): δ = 160.6 (Cq), 153.8 (Cq), 134.1 (Cq), 130.2 (Cq), 129.3 
(2 x CH-m-Phe-O), 129.1 (Cq), 125.0 (C-6Bf), 124.9 (Cq), 119.7(C-4Bf), 
115.9 (2 x C-o-Phe-O), 112.7 (C-7Bf), 110.5 (Cq), 71.8 (CH-O), 70.4 
(CH2-O), 64.1 (CH2-OH), 9.3 (CH3-Bf). ESI-MS: calculated for C18H18ClO4 
[M+H]+ 333.1, found 333.2 
1-(4-(5-bromo-3-methylbenzofuran-2-yl)phenoxy)-3-(N-
methylpiperazyl) propan-2-ol (32): To a solution of the epoxide 24 (0.1 
mmol) in dry EtOH (1 mL) 1-methylpiperazine was added (0.5 mmol). 
The reaction was stirred for 2 h at 80 °C, monitoring by TLC (7:3 
Toluene:EtOAc and 9:1 CHCl3:MeOH). The solvent was evaporated 
under vacuum and the crude purified by flash chromatography (95:5 
CHCl3:MeOH) to afford 32 in 45% yield. 1H-NMR (400 MHz, CDCl3): δ = 
7.72 (d, Jo-m = 9.2 Hz, 2 H, 2xH-m-Phe-O), 7.62 (d, J4-6 = 1.5 Hz, 1 H, H4-
Bf), 7.35 (dd, J6-7 = 8.4 Hz, 2 H, H6Bf), 7.32 (d, 1 H, H7-Bf), 7.03 (d, 2 H, 
2xH-m-Phe-O), 4.18-4.12 (m, 1 H, CH-O), 4.05 (d, Jvic = 4.9 Hz, 2 H, 
CH2-O), 2.18-2.16 (bs, 2 H, NCH2CH2NMe), 2.60-2.58 (m, 8 H, 
CH2NCH2CH2NMe), 2.40 (s, 3 H, CH3-N), 2.39 (s, 3 H, CH3Bf) ppm. 13C-
NMR (100 MHz, CDCl3): δ = 158.9 (Cq), 152.5 (Cq), 152.2 (Cq), 133.5 
(Cq), 128.4 (2 x C-m-Phe-O), 126.8 (C-6Bf), 124.1 (Cq), 122.0 (C-4Bf), 
115.5 (Cq), 115.0 (2 x C-m-Phe-O), 112.4 (C-7Bf), 70.4 (CH2-O), 65.7 
(CH-OH), 60.5 (CH2NCH2CH2NMe), 55.0 (CH2NCH2CH2NMe), 45.7 
(CH3-N), 9.3 (CH3Bf) ppm. ESI-MS: calcd for C23H28BrN2O3 [M+H]+ 460.4, 
found 459.9 
4-[5-chloro-3-methylbenzofuran-2-yl]-phenoxyacetylmorpholine 
(34): To a solution of 33 (19.7 mg, 0.062 mmol) in dry THF (1.2 mL) were 
added EDC·HCl (15.5 mg, 0.081 mmol) and TEA (22 µL, 0.155 mmol) 
and the reaction was stirred at 30 °C under nitrogen atmosphere for 20 h. 
Morpholine (11 µL, 0.124 mmol) was added and the reaction stirred for 2 
h at 45 °C. After the reaction was complete (TLC 95:5:0.1 
CHCl3:MeOH:HCOOH) the reaction mixture was diluted with Et2O and 
washed with 0.1 M HCl. The organic phase was dried over anhydrous 
Na2SO4 and the solvent was evaporated in vacuo. The crude product 
was purified by flash chromatography (4:6 Hex:EtOAc) obtaining the 
desired product 34 (8.4 mg) as a white solid in 35% yield. 1H-NMR (400 
MHz, CDCl3): δ =7.73 (d, Jo-m = 8.0 Hz, 2 H, 2 x CH-m-Ph-O), 7.47 (s, 1 
H, H-4Bf), 7.37 (d, J7-6 = 8.4 Hz, 1 H, H-7Bf), 7.21 (d, 1 H, H-6Bf), 7.06 (d, 
2 H, 2 x C-o-Ph-O), 4.76 (s, 2 H, CH2OAr), 3.66 (m, 8 H, CH2-Morf), 2.41 
(s, 3 H, CH3-Bf) ppm. 13C-NMR (100 MHz, CDCl3): δ = 166.5 (C=O), 
157.8 (Cq), 152.2 (Cq), 132.8 (Cq), 128.5 (2 x C-m-Ph-O), 128.1 (Cq), 
124.9 (Cq), 124.2 (C-6Bf), 118.9 (C-4Bf), 115.0 (2 x C-o-Ph-O), 111.9 (C-
7Bf), 67.8 (CH2OAr), 67.0 (2xCH2O), 46.1 (CH2N), 42.6 (CH2N), 9.5 
(CH3-Bf) ppm. HRMS (ESI): Calcd for C21H20ClNNaO4 [M+Na]+ 408.0979, 
Found 408.1089 
4-[5-chloro-3-methylbenzofuran-2-yl]-phenoxyacetyl-1-
methylpiperazine (35): Oxalyl chloride (0.27 mmol, 2.0 M solution in dry 
DCM) was added to a solution of 33 (28.8 mg, 0.091 mmol) in dry DCM 
(0.9 mL) and the reaction was stirred at reflux under nitrogen atmosphere 
for 2 h. The solvent was co-evaporated with toluene at reduced pressure, 
the crude was re-dissolved in dry DCM (0.1 mL) and 1-methylpiperazine 
(300 µL, 2.7 mmol) was added. The reaction was stirred at 40 °C 
overnight (TLC 9:1:0.1 CHCl3:MeOH:TEA). The solvent was evaporated 
in vacuo and the crude was purified using an automatic system (SiO2, 
DCM:MeOH gradient from 0 to 14% MeOH) obtaining the desired 
product 35 (28 mg) as a white solid in 78% yield. 1H-NMR (400 MHz, 
CDCl3): δ = 7.73 (d, Jo-m = 8.9 Hz, 2 H, 2 x CH-m-Ph-O), 7.46 (d, J4-6 = 
2.1 Hz, 1 H, H4-Bf), 7.36 (d, J7-6 = 8.6 Hz, 1 H, H7-Bf), 7.21 (dd, 1 H, H6-
Bf), 7.06 (d, 2 H, 2 x CH-o-Ph-O), 4.75 (s, 2 H, CH2OAr), 3.70 (m, 2 H, 
CH2N), 3.66 (m, 2 H, CH2N), 2.46 (m, 4 H, 2 x CH2NMe), 2.40 (s, 3 H, 
CH3-Bf), 2.34 (s, 3 H, NMe) ppm. 13C-NMR (100 MHz, CDCl3): δ = 166.3 
(C=O), 157.9 (Cq), 152.2 (Cq), 132.8 (Cq), 128.5 (2 x C-m-Ph-O), 128.1 
(Cq), 124.8 (Cq), 124.2 (C6-Bf), 118.9 (C4-Bf4), 115.0 (2 x C-o-Ph-O), 
111.9 (C7-Bf), 109.9 (Cq), 67.8 (CH2OAr), 55.1 (CH2N), 54.6 (CH2N), 
46.0 (NCH3), 45.1 (CH2NMe), 41.9 (CH2NMe), 9.5 (CH3-Bf) ppm. ESI-
MS: Calculated for C22H24ClN2O3 [M+H]+ 399.1475, Found 399.1793 
4-[5-chloro-3-methylbenzofuran-2-yl]phenyl-2,3,4-tri-O-benzoyl-6-
azido-α-D-mannopyranoside (37): Azide 36[14] (0.17 g, 0.25 mmol) and 
phenol 1a (58 mg, 0.23 mmol) were co-evaporated three times with 
toluene and dissolved in dry DCM (4.6 mL) under nitrogen atmosphere. 
To the solution freshly activated 4 Å molecular sieves were added. The 
reaction mixture was cooled at -30 °C and TMSOTf (8.3 µL, 46 µmol) 
was slowly added. The reaction was stirred for 30 min and followed by 
TLC (9:1 toluene:EtOAc, Rf=0.91). To the solution TEA (0.13 mL) was 
added. The reaction was warmed to room temperature and concentrated 
in vacuum. The crude was purified by flash chromatography (8:1:1 
Hex:EtOAc:toluene) leading to product 37 (87 mg, 0.13 mmol) in 50% 
yield. 1H-NMR (400 MHz, CDCl3): δ = 8.16 (d, Jo-m = 7.6 Hz, 2 H, 2x o-
CH-Bz), 7.98 (d, Jo-m= 7.6 Hz 2 H, 2x o-CH-Bz), 7.87 (d, Jo-m = 7.8 Hz, 2 
H, 2x o-CH-Bz), 7.81 (d, Jp-m = 9.0 Hz, 2 H, 2x m-CH-Bz), 7.70-7.63 (m, 1 
H, p-CH-Bz), 7.57-7.50 (m, 3 H, p-CH-Bz, 2 x m-CH-Bz), 7.49 (d, J4-6 = 
2.2 Hz, 1 H, H-4Bf), 7.47-7.44 (m, 1 H, p-CH-Bz), 7.42-7.37 (m, 2 H, 2 x 
m-CH-Bz), 7.39 (d, J7-6 = 8.5 Hz, 1 H, H-7Bf), 7.34 (d, 2 H, H-o-Phe-O), 
7.32-7.27 (m, 2 H, 2 x m-CH-Bz), 7.23 (dd, 1 H, H-6Bf), 6.14 (dd, J3’-4’ = 
10.0 Hz, J3’-2’ = 3.2 Hz, 1 H, H3), 6.00 (dd, J4’-5’ = 10.0 Hz, 1 H, H4’), 5.93-
5.90 (m, 1 H, H2’), 5.9 (d, J1’-2’ = 1.9 Hz, 1 H, H1’), 4.43-4.37 (m, 1 H, H5’), 
3.54 (dd, J5’-6’a = 6 Hz, J6’a-6’b = 13.3 Hz, 1 H, H6’a), 3.45 (dd, J5’-6’b=2.5 Hz, 
1 H, H6’b), 2.44 (s, 3 H, CH3-Bf) ppm. 13C-NMR (100 MHz, CDCl3): δ = 
165.6 (C=O Bz), 165.5 (C=O), 155.6 (Cq Bf), 152.1 (Cq Bf), 151.8 (Cq Bf), 
133.8 (p-CH-Bz), 133.7 (p-CH-Bz), 133.4 (p-CH-Bz), 132.7 (Cq), 130.0 
(o-CH-Bz), 129.9 (o-CH-Bz), 129.8 (o-CH-Bz), 129.0 (CqBz), 128.9 
(CqBz), 128.8 (m-CH-Bz), 128.7 (CqBz), 128.6 (m-CH-Bz), 128.4 (C-m-
Phe-O), 128.0 (Cq Bf), 126.0 (Cq Bf), 124.3 (C-6Bf), 118.9 (C-4Bf), 116.7 
(C-o-Phe-O), 111.9 (C-7Bf), 110.2 (Cq Bf), 95.7 (C1’), 71.2 (C5’), 70.1 (C2’), 
69.5 (C3’), 67.4 (C4’), 51.2 (C6), 9.4 (CH3-Bf) ppm. ESI-MS:calcd for 
C42H32ClN3NaO9 [M+Na]+ 781.2, found 781.1 
4-[5-chloro-3-methylbenzofuran-2-yl]phenyl-6-azido-α-D-
mannopyranoside (38): Compound 37 (20 mg, 26 µmol) was dissolved 
in MeOH (0.26 mL) under nitrogen atmosphere. To the reaction mixture 
MeONa (3 mg, 53 µmol) was added. The reaction was stirred for 2.5 h 
and was followed by TLC (7:3 Hex:EtOAc). The solution was diluted with 
MeOH and treated with Amberlite IR120 to reach pH=7. The crude was 
purified by flash chromatography (96:4 DCM:MeOH, Rf=0.28) leading to 
product 38 (7 mg, 17 µmol) in 79% yield. [α]D25= +81 (c=0.1, MeOH). 1H-
NMR (400 MHz, CD3OD): δ = 7.74 (d, Jo-m = 8.8 Hz, 2 H, H-m-Phe-O), 
7.50 (d, J4-6 = 2.0 Hz, 1 H, H-4Bf), 7.40 (d, J7-6 = 8.7 Hz, 1 H, H-7Bf), 7.26 
(d, 2 H, H-o-Phe-O), 7.21 (d, 1 H, H-6Bf), 5.59 (d, J1-2 = 1.6 Hz’, 1 H, H1’), 
4.07 (dd, J2’-3’ = 3.4 Hz, 1 H, H2’), 3.92 (dd, J3’-4’ = 8.8 Hz, 1 H, H3’), 3.78-
3.67 (m, 2 H, H4’,H5’), 3.50-3.40 (m, 2 H, H6’), 2.44 (s, 3 H, CH3-Bf) ppm. 
13C-NMR (100 MHz, CD3OD): δ = 157.4 (Cq), 153.2 (Cq), 133.8 (Cq), 
129.1 (C-m-Phe-O), 129.0 (Cq), 126.1 (Cq), 125.0 (C-6Bf), 119.6 (C-4Bf), 
117.5 (C-m-Phe-O), 112.6 (C-7Bf), 110.8 (Cq), 99.4 (C1’), 74.5 (C5’), 72.0 
(C3’), 71.5 (C2’), 69.0 (C4’), 52.6 (C6’), 9.4 (CH3-Bf) ppm. ESI-MS: calcd 
for C21H21ClN3NaO9 [M+H]+ 446.1, found 446.5 
4-[5-chloro-3-methylbenzofuran-2-yl]phenyl-2,3,4-tri-O-acetyl-6-
azido-β-D-glucopyranoside (40): 2,3,4-O-acetyl-6-azido-α-D-
glucopyranosyl bromide 39[15] (189 mg, 0.48 mmol) and benzofuran 1a 
(40 mg, 0.16 mmol) were diluted in CHCl3 (1.6 mL). To the reaction 
mixture, Bu4NHSO4 (27 mg, 0.08 mmol) was added, followed by K2CO3 
(132.7 mg, 138.1 mmol) and water (6.63 µL, 18 mmol). The conversion 
was detected through TLC (7:3 Hex:EtOAc, Rf=0.35). After 15 h of 
stirring, a change in color from yellow to brown was observed and the 
reaction was diluted with CHCl3. 1 M HCl was added until acidic pH. The 
organic layer was extracted with NaHCO3 (2x20 mL), dried over Na2SO4 
and concentrated in vacuum. The desired product 40 (35 mg, 0.06 mmol) 
was purified by flash chromatography (8:2 Hex:EtOAc) and obtained in 
40% yield. 1H-NMR (400 MHz, CDCl3): δ = 7.74 (d, Jo-m = 8.8 Hz, 2 H, H-
m-Phe-O), 7.48 (d, J4-6 = 2.0 Hz, 1 H, H-4Bf), 7.37 (d, J7-6 = 8.8 Hz, 1 H, 
H-7Bf), 7.22 (d, 1 H, H-6Bf), 7.18 (d, 2 H, H-o-Phe-O), 5.34-5.29 (m, 2 H, 
H2’, H3’), 5.18-5.14 (m, 1 H, H1’), 5.10-5.03 (m, 1 H, H4’), 3.95-3.88 (m, 1 
H, H5’), 3.51 (dd, J5’-6’a = 2.4 Hz, J6’a-6’b = 11 Hz, 1 H, H6’a), 3.43 (dd, J5’-6’b 
= 8 Hz, 1 H, H6’b), 2.41 (s, 3 H, CH3-Bf), 2.09 (s, 3 H, OCOCH3), 2.08 (s, 
3 H, OCOCH3), 2.05 (s, 3 H, OCOCH3) ppm. 13C-NMR (100 MHz, 
CDCl3): δ = 169.6 (Cq=O), 169.4 (Cq=O), 169.3 (Cq=O), 156.7 (Cq), 152.1 
(Cq), 151.8 (Cq), 132.7 (Cq), 128.3 (C-m-Ph-O), 128.1 (Cq), 126.3 (Cq), 
124.3 (C-6Bf), 119.0 (C-4Bf), 117.2 (C-o-Ph-O), 111.9 (C-7Bf), 110.3 (Cq), 
98.9 (C1’), 74.3 (C5’), 72.5 (C3’), 71.3 (C2’), 71.0 (C4’), 30.5 (C6’), 20.7 (3x 
CH3-Ac), 9.5 (CH3-Bf) ppm. ESI-MS: calcd for C27H26ClN3NaO9 [M+Na]+ 
595.1, found 594.9 
4-[5-chloro-3-methylbenzofuran-2-yl]phenyl-6-azido-β-D-
glucopyranoside (41): Compound 40 (37 mg, 0.06 mmol) was 
suspended in MeOH (900 µL) at 40 °C under nitrogen atmosphere. A 1 M 
solution of MeONa in MeOH (180 µL, 0.18 mmol) was added. The 
reaction was followed by TLC (9:1 CHCl3:MeOH, Rf=0.37) After stirring at 
40 °C for 3 days, the reaction was quenched with 1 M acetic acid in 
MeOH (189 µL, 0.18 mmol) and concentrated in vacuo. DCM was added 
to the crude and after centrifugation, the liquid phase containing all the 
impurities was pipetted out. The resulting pellet was re-suspended in 
MeOH and stirred at 50 °C for 5 min before centrifuging. Unreacted 
starting material (40, 4 mg) was recovered in the surnatant. The 
remaining pellet contained the final product 41, obtained in 64% yield (17 
mg, 0,038mmol) and sufficient purity, as judged by 1H-NMR (d6-acetone). 
[α]D25= -58 (c=0.1, Acetone). 1H-NMR (400 MHz, (CD3)2CO): δ = 7.79 (d, 
Jo-m = 8.8 Hz, 2 H, H-m-Phe-O), 7.62 (d, J4-6 = 2.5 Hz, 1 H, H-4Bf), 7.51 
(d, J7-6 = 8.8 Hz, 1 H, H-7Bf), 7.35-7.24 (m, 3 H, H-o-Phe-O, H-6Bf), 5.13 
(d, J1’-2’ = 4.6 Hz, 1 H, H1’), 3.91 (d, J5’-6’a = 2.0 Hz, J6’a-6’b = 11.0 Hz, 1 H, 
H6’a), 3.85-3.74 (m, 1 H, H5’), 3.66-3.50 (m, 3 H, H2’, H3’, H6’), 3.49-3.38 
(m, 1 H, H4’), 2.46 (s, 3 H, CH3-Bf) ppm. 13C-NMR (100 MHz, (CD3)2CO): 
δ = 158.9 (Cq), 133.7 (Cq), 128.9 (C-m-Ph-O), 128.6 (Cq), 125.6 (2xCq), 
125.0 (C-6Bf), 119.8 (C-4Bf), 117.8 (C-o-Ph-O), 112.8 (C-7Bf), 110.8 (Cq), 
101.6 (C1’), 77.5 (C3’), 76.6 (C5’), 74.6 (C2’), 73.2 (C4’), 45.5 (C6’), 9.3 
(CH3-Bf) ppm.ESI-MS: calcd for C21H20ClNaN3O6 [M+Na]+ 468.9, found 
468.7 
2,3,4-tri-O-acetyl--L-arabinopyranosyl bromide 50:[16] La(OTf)3 (12 
mg, 0.02 mmol) was added to a suspension of L-arabinose (1.0 g, 6.7 
mmol) in acetic anhydride (2.6 mL) and the reaction was stirred at 30 °C 
under nitrogen atmosphere for 1 h (TLC 6:4 Hex:EtOAc). The reaction 
mixture was diluted with DCM, the organic phase washed with NaHCO3 
and brine and dried over anhydrous Na2SO4. The solvent was 
evaporated in vacuo and the crude product (547 mg) was purified using 
an automatic system (SiO2, Hex:EtOAc gradient) obtaining the 1,2,3,4-
tetra-O-acetyl-α/β-L-arabinopyranoside (L-Ara(OAc)4) as a white solid in 
α:β ratio of 1:1 (1.3 g, 60% yield). 1H-NMR (400 MHz, CDCl3): δ = 6.36 (d, 
J1-2 = 3.1 Hz, 1 H, H1β), 5.67 (d, J1-2 = 7.0 Hz, 1 H, H1α), 5.41-5.35 (m, 3 
H, H2β, H3β, H4β), 5.33-5.27 (m, 2 H, H2α, H4α), 5.12 (dd, J2-3 = 9.1 Hz, J3-4 
= 3.5 Hz, 1 H, H3α), 4.11-4.02 (m, 2 H, H5bα, H5bβ), 3.87-3.75 (m, 2 H, H5aα, 
H5aβ), 2.22-2.01 (m, 24 H, OCOCH3) ppm. 13C-NMR (100 MHz, CDCl3): δ 
= 170.5 (OCOCH3), 170.3 (OCOCH3), 170.2 (OCOCH3), 169.9 
(OCOCH3), 169.9 (OCOCH3), 169.4 (OCOCH3), 169.1 (OCOCH3), 169.1 
(OCOCH3), 92.1 (C1α), 90.2 (C1β), 69.9 (C3α), 68.5, 68.1, 67.1, 67.01, 
66.7, (C2β, C3β, C4β, C2α, C4α), 63.9, 62.8 (C5β, C5α), 20.9-20.6 (OCOCH3) 
ppm. HBr (33% in AcOH, 21.9 mL, 12.3 mmol) was added dropwise to L-
Ara(OAc)4 (1.3 g, 4.1 mmol) at 0 °C under nitrogen atmosphere. The 
reaction mixture was warmed to room temperature and after 15 min DCM 
was added (2.4 mL). The reaction was then stirred at room temperature 
for 25 min (TLC 65:35 Hex:EtOAc). The reaction was quenched adding 
ice and DCM at 0 °C. The organic phase was washed with cold water 
and cold saturated NaHCO3 solution (3x10 mL) and finally dried over 
anhydrous Na2SO4. The solvent was evaporated in vacuo and the crude 
product 50 (1.1 g) was obtained in 79% yield as the single β isomer and 
used without further purification (the product is not stable on silica). 1H-
NMR (400 MHz, CDCl3): δ = 6.69 (d, J1-2 = 3.7 Hz, 1 H, H1), 5.39 (m, 2 H, 
H3, H4), 5.08 (m, 1 H, H2), 4.20 (d, J5eq -5ax = 13.3 Hz, 1 H, H5eq), 3.93 (dd, 
J5ax-4 = 1.9 Hz, 1 H, H5ax), 2.15 (s, 3 H, OCOCH3), 2.11 (s, 3 H, OCOCH3), 
2.02 (s, 3 H, OCOCH3) ppm. 13C-NMR (100 MHz, CDCl3): δ = 170.2 
(OCOCH3), 170.2 (OCOCH3), 169.9 (OCOCH3), 89.8 (C1), 68.0, 67.9, 
67.7 (C3, C2, C4), 64.8 (C5), 20.9 (OCOCH3), 20.8 (OCOCH3), 20.7 
(OCOCH3) ppm. 
2,3,4-tri-O-acetyl--D-arabinopyranosyl bromide: Synthesized as 
described above for the L-enantiomer with similar yields and identical 
spectral data. 
4-[5-chloro-3-methylbenzofuran-2-yl]-phenoxy-α-L-
arabinopyranoside (44): TBAHSO4 (20 mg, 0.056 mmol), potassium 
carbonate (98.7 mg, 0.71 mmol) and water (5 µL, 5%w/w(K2CO3)) were 
added to a mixture of 1a (30.7 mg, 0.12 mmol) and 2,3,4-tri-O-acetyl--L-
arabinopiranosyl bromide 50 (80.5 mg, 0.24 mmol) in chloroform (0.6 mL). 
The reaction was vigorously stirred at room temperature for 3 h (TLC 6:4 
Hex:EtOAc). The reaction mixture was diluted with chloroform, the 
organic phase was washed with 0.1M HCl aq., saturated NaHCO3 
solution and brine. The organic phase was dried over anhydrous Na2SO4. 
The solvent was evaporated in vacuo and the crude product (97.1 mg) 
was purified using an automatic system (SiO2, Hex:EtOAc gradient) 
obtaining the desired product (50.8 mg) as a white solid in 83% yield. 
[α]D25 = +24 (c 0.5, DCM). 1H-NMR (400 MHz, CDCl3): δ = 7.73(d, Jo-m = 
8.8 Hz, 2 H, 2 x H-m-Phe-O), 7.47 (d, J4-6 = 2.1 Hz, 1 H, H-4Bf), 7.37 (d, 
J7-6 = 8.6 Hz, 1 H, H-7Bf), 7.22 (dd, 1 H, H-6Bf), 7.12 (d, 2 H, 2 x H-o-
Phe-O), 5.46 (dd, J1’-2’ = 8.7, J3’-2’ = 6.3 Hz, 1 H, H2’), 5.39-5.31 (m, 1 H, 
H4’), 5.23-5.12 (m, 2 H, H1’, H3’), 4.15 (dd, J5’ax-5’eq = 12.8, J4’-5’eq = 4.1 Hz, 
1 H, H5’eq), 3.79 (dd, J4’-5’ax = 2.1 Hz, 1 H, H5’ax), 2.41 (s, 3 H, CH3 Bf), 
2.16 (s, 3 H, OCOCH3), 2.11 (s, 3 H, OCOCH3), 2.10 (s, 3 H, OCOCH3) 
ppm. 13C-NMR (100 MHz, CDCl3): δ = 170.4 (OCOCH3), 170.3 
(OCOCH3), 169.6 (OCOCH3), 156.7 (Cq), 152.2 (Cq), 151.9 (Cq), 132.7 
(Cq), 128.4 (C-m-Ph-O), 128.1 (Cq), 126.1 (Cq), 124.4 (C-6Bf), 119.0 (C-
4Bf), 117.1 (C-o-Ph-O), 112.0 (C-7Bf), 110.2 (Cq), 98.7 (C1’), 69.8 (C3’), 
69.0 (C2’), 67.2 (C4’), 62.8 (C5’), 21.0 (OCOCH3), 20.9 (OCOCH3), 20.9 
(OCOCH3), 9.5 (CH3-Bf) ppm. ESI-MS: Calculated for C26H25ClKO9 
[M+K]+ 555.2found 554.9. 1M MeONa in MeOH (200 μL) was added to a 
solution of 4-[5-chloro-3-methylbenzofuran-2-yl]-phenoxy-2,3,4-triacetyl-
α-L-arabinopyranoside (50.7 mg, 0.098 mmol) in MeOH (0.8 mL). The 
reaction was stirred under nitrogen atmosphere at room temperature for 
1 h (TLC 6:4 Hex:EtOAc) and then quenched with Amberlite IR-120 H+. 
The resin was filtered off, the solvent was evaporated in vacuo and the 
crude product (43.5 mg) was purified using an automatic system (SiO2, 
DCM:MeOH gradient from 0 to 25% MeOH) obtaining the desired 
product 44 (28.1 mg) as a white solid in 73% yield. 1H-NMR (400 MHz, 
CD3OD): δ = 7.74 (d, Jo-m = 8.9 Hz, 2 H, 2 x H-m-Phe-O), 7.53 (d, J4-6 = 
2.0 Hz, 1 H, H4-Bf), 7.42 (d, J7-6 = 8.6 Hz, 1 H, H7-Bf), 7.25-7.18 (m, 3 H, 
H6-Bf, 2 x H-o-Phe-O), 4.94 (d, J1’-2’ = 7.2Hz, 1 H, H1’), 3.96 (dd, J5’eq-5’ax 
= 12.4 Hz, J5’eq-4’ = 2.8 Hz, 1 H, H5’eq), 3.90 (m, 1 H, H4’), 3.86 (dd, J3’-2’ = 
9.0 Hz, 1 H, H2’), 3.75 (d, 1 H, H5’ax), 3.67 (dd, J3’-4’ = 3.5 Hz, 1 H, H3’), 
2.40 (s, 3 H, CH3 Bf) ppm. 13C-NMR (100 MHz, CD3OD): δ = 159.1 (Cq), 
153.5 (Cq), 153.4 (Cq), 134.0 (Cq), 129.2 (Cq), 129.1 (C-m-Ph-O), 126.2 
(Cq), 125.2 (C6-Bf), 119.8 (C4-Bf), 118.0 (C-o-Ph-O), 112.8 (C7-Bf), 
111.0 (Cq), 102.5 (C1’), 74.1 (C3’), 72.2 (C2’), 69.6 (C4’), 67.2 (C5’), 9.3 
(CH3 Bf) ppm. HRMS: Calculated forC20H19ClNaO6 [M+Na]+ 413.07624 
Found 413.07695. [α]D25 = -9.2 (c0.1, MeOH) 
4-[5-chloro-3-methylbenzofuran-2-yl]-phenoxy-α-D-
arabinopyranoside (45): Synthesized as described above for the L-
enantiomer with similar yields and identical spectral data. 
1,2,3,4-tetra-O-benzoyl-α/β-L-lyxopyranose:[25] Benzoyl chloride (3 mL, 
26.7 mmol) was added dropwise to a solution of L-Lyxose (501.7 mg, 3.3 
mmol) in pyridine (8 mL) at 0 °C under nitrogen atmosphere. DMAP (40 
mg, 0.33 mmol) was added and the reaction was warmed to room 
temperature and stirred for 2 h (TLC 7:3 Hex:EtOAc). The reaction 
mixture was quenched with ice and diluted with EtOAc. The organic 
phase was washed with 2 M HCl (2x30 mL), water (1x30 mL), saturated 
NaHCO3 solution (1x40 mL) and brine (1x30 mL). The organic phase was 
dried over anhydrous Na2SO4, the solvent was evaporated in vacuo and 
the crude product (2.5 g) was purified using an automatic system (SiO2, 
Hex:EtOAc gradient from 0 to 60% EtOAc) obtaining the desired product 
(1.8 g) as a white solid in 73:27 α:β ratio (from H11H-NMR signal ratio) in 
quantitative yield. 1H-NMR (400 MHz, CDCl3): δ = 8.20-7.27 (m, 20 H, 
CH-Bz), 6.66 (d, J1-2 = 3.5 Hz, 1 H, H1β), 6.53 (d, J1-2 = 3.1 Hz, 1 H, H1α), 
6.07 (dd, J3α-4α = 9.3 Hz, J3α-2α = 3.5 Hz, 1 H, H3α), 5.96-5.90 (m, 2 H, H2β, 
H3β), 5.89 (t, 1H, H2α), 5.81 (dt, J4α-5αax = 9.2 Hz, J4α-5αeq = 5.0 Hz, 1 H, 
H4α), 5.55 (m, 1 H, H4β), 4.61 (dd, J5βeq-5βax = 13.0 Hz, J5βeq-4β = 2.4 Hz, 1 
H, H5βeq), 4.37 (dd, J5αeq-5αax = 11.5 Hz, 1 H, H5αeq), 4.11-4.01 (m, 1 H, 
H5αax, H5βax) ppm. 13C-NMR (100 MHz, CDCl3): δ = 165.8, 165.7, 165.5, 
165.5, 165.4, 165.2, 164.4 (C=O Bz), 134.1, 133.9, 133.8, 133.7, 133.7, 
133.6, 130.3, 130.3, 130.2, 130.1, 130.0, 129.9, (CH-Bz), 129.5, 129.4, 
129.2, 129.1, 128.9 (Cq Bz), 128.9, 128.8, 128.7, 128.7, 128.6, 128.6 
(CH-Bz), 91.7 (C1α), 90.2 (C1β), 69.4, 69.4 (C2α, C3α), 69.0 (C4β), 67. 7 
(C2β), 67.6 (C4α), 66.6(C3β), 62.5 (C5α), 60.8(C5β) ppm. 
2,3,4-tri-O-benzoyl-α/β-L-lyxopyranosyl bromide:[25] HBr (33% in 
AcOH, 2 mL, 35.3 mmol) was added dropwise to /β-L-Lyx(OBz)4 (1.0 g, 
1.4 mmol) at 0 °C under nitrogen atmosphere. The reaction mixture was 
warmed to room temperature and after 15 min DCM was added (0.8 mL). 
The reaction was then stirred at room temperature for 20 minutes (TLC 
7:3 Hex:EtOAc). The reaction was quenched adding ice and DCM at 0 °C. 
The organic phase was washed with cold water and cold saturated 
NaHCO3 solution (3x10 mL), dried over anhydrous Na2SO4. The solvent 
was evaporated in vacuo and the crude product (680 mg) was obtained 
in 9:1 α:β ratio (from H1 1H-NMR signal ratio) in 73% yield and used 
without further purification (the product is not stable on silica). 1H-NMR 
(400 MHz, CDCl3): δ = 8.32-7.27 (m, 15 H, CH-Bz), 6.82 (d, J1β-2β = 4.1 
Hz, 1 H, H1β), 6.54 (d, J1α-2α = 1.5 Hz, 1 H, H1α), 6.29 (dd, J3α-2α = 3.5 Hz, 
J3α-4α = 10.3 Hz, 1 H, H3α), 5.89 (dd, 1 H, H2α), 5.86 (m, 1 H, H3β), 5.84 (td, 
J4α-5αax = 10.6 Hz, J4α-5αeq = 5.7 Hz, 1 H, H4α), 5.69 (t, J = 4.2 Hz, 1 H, H2β), 
5.39 (m, 1 H, H4β), 4.60 (dd, J5βeq-5βax = 13 Hz, J5βeq-4β = 1 Hz, 1 H, H5βeq), 
4.39 (dd, J5αeq-5αax = 11.3 Hz, J5αeq-4α = 5.7 Hz, 1 H, H5αeq), 4.14 (m, 1 H, 
H5βax), 4.09 (t, J5αax-4α = 11.3 Hz, 1 H, H5αax) ppm. 13C-NMR (100 MHz, 
CDCl3): δ = 165.9, 165.5, 165.3, 165.2 (C=O Bz), 134.0, 134.0, 133.9, 
133.8, 133.8, 133.5 (p-CH-Bz), 130.5, 130.2, 130.1, 130.0, 129.9 (o-CH-
Bz), 129.1, 129.1, 129.1, 129.0, 128.9 (Cq Bz), 128.9, 128.8, 128.8, 
128.7, 128.6, 128.5 (m-CH-Bz), 85.4 (C1β), 84.5 (C1α), 73.3 (C2α), 68.9 
(C4β), 68.3 (C3α), 67.1 (C4α), 66.5 (C3β), 66.3 (C2β), 63.5 (C5α), 61.4 (C5β) 
ppm. 
2,3,4-tri-O-benzoyl-α/β-L-lyxopyranosyl-O-Box (53): AgOBox (534 mg, 
2.2 mmol), 2,6-lutidine (225 μL, 1.9 mmol) and TBAI (28 mg, 0.08 mmol) 
were added to a solution of 2,3,4-tri-O-benzoyl-α/β-L-lyxopyranosyl 
bromide (580 mg, 1.1 mmol) in dry DCM (8.6 mL) under argon 
atmosphere. The reaction mixture was stirred at 50°C for 2 h (TLC 8:2 
Hex:EtOAc) and then diluted with DCM. The organic phase was washed 
with 0.1 M NaOH (2x10 mL), water (2x10 mL) and brine (1x10 mL). The 
organic phase was dried over anhydrous Na2SO4, the solvent was 
evaporated in vacuo and the crude product (150 mg) was purified using 
an automatic system (SiO2, Hex:EtOAc gradient from 0% to 40% EtOAc) 
obtaining the desired product (135.7 mg) in 84:16 α:β ratio (from H11H-
NMR signal ratio) as a white solid in 24% yield. 1H-NMR (400 MHz, 
CDCl3): δ = 8.33-7.16 (m, 19 H, CH-Bz, CH OBox), 6.75 (d, J1β-2β = 4 Hz, 
1 H, H1β), 6.55 (d, J1α-2α = 2.6 Hz, 1 H, H1α), 6.09 (dd, J3α-4α = 9.6 Hz, J2α-
3α = 3.4 Hz, 1 H, H3α), 5.98 (dd, 1 H, H2α), 5.96 (m, 1 H, H3β), 5.89 (m, 1 H, 
H2β), 5.86 (td, J4α-5αeq = 5.2 Hz, 1 H, H4α), 5.47 (m, 1 H, H4β), 4.62 (dd, 
J5βeq-5βax = 13.4 Hz, J5βeq-4β = 1.6 Hz, 1 H, H5βeq), 4.40 (dd, J5αeq-5αax = 
11.5Hz, 1 H, H5αeq), 4.12 (dd, J5αax-4α = 10.5 Hz 1 H, H5αax), 4.11 (m, 1 H, 
H5βax) ppm. 13C-NMR (100 MHz, CDCl3): δ = 165.8, 165.5, 165.3 (C=O 
Bz), 161.3 (Cq OBox), 148.7 (Cq OBox), 140.6 (Cq OBox), 134.0, 133.9, 
133.8, 133.7, 133.6, 133.6, 133.5, 130.7, 130.4, 130.2, 130.1, 130.0, 
129.9 (CH-Bz), 129.0 (Cq Bz), 128.9 (Cq Bz), 128.8 (Cq Bz), 128.8, 128.7, 
128.7, 128.6, 128.6, 128.5, 125.7, 124.8, 124.1, 123.7, 123.4, 118.9, 
110.2 (CH Ar), 98.0 (C1α), 96.8 (C1β), 69.0 (C2α, C4β), 68.7 (C3α), 67.1 
(C4α), 66.6 (C3β), 66.0 (C2β), 62.3 (C5α) ppm. ESI-MS: Calculated 
forC33H25NNaO9 [M+Na]+ 602.1 Found 602.2 Calculated for [2M+Na]+ 
1181.3 Found 1180.9 
4-[5-chloro-3-methylbenzofuran-2-yl]-phenoxy-2,3,4-tribenzoyl--L-
lyxopyranoside (54) and 4-[5-chloro-3-methylbenzofuran-2-yl]-
phenoxy-2,3,4-tribenzoyl--L-lyxopyranoside (55): 2,3,4-tri-O-benzoyl-
α/β-L-lyxopyranosyl-O-Box (96.5 mg, 0.17 mmol) and 1a (35.9 mg, 0.14 
mmol) were dissolved in dry 1,2-dichloroethane (0.7 mL) under argon 
atmosphere. The solution was cooled to -78 °C and 0.1 M TMSOTf in dry 
1,2-dichloroethane (170 μL, 0.017 mmol) was added dropwise to the 
frozen mixture. The reaction mixture was warmed to -30 °C (just above 
the m.p. of the solvent) and stirred for 1-2 minutes. After completion (TLC 
9:1 Toluene:EtOAc) the reaction mixture was diluted with DCM and the 
organic phase was washed with 0.1 NaOHaq (2x5 mL) and water (1x5 
mL). The organic phase was dried over anhydrous Na2SO4, the solvent 
was evaporated in vacuo and the crude product (107.6 mg) was purified 
using an automatic system (SiO2, Hex:EtOAc gradient from 0% to 20% 
EtOAc) obtaining a 56:44 α:β anomeric mixture (from H5eq1H-NMR signal 
ratio). The anomers were separated by flash chromatography (9:1 
Toluene:Hex obtaining 38.6 mg of the  product 54 (Rf= 0.3, 40% yield) 
and 28.1 mg of  product 55 (Rf= 0.1, 29% yield). α anomer (54) [α]D25 = 
-29 (c=0.43, DCM). 1H-NMR (400 MHz, CDCl3): δ = 8.15 (d, Jo-m = 7.3 Hz, 
2 H, 2x o-CH-Bz), 8.01 (d, Jo-m = 7.3 Hz, 2 H, 2x o-CH-Bz), 7.92 (d, Jo-m = 
7.3 Hz, 2 H, 2x o-CH-Bz), 7.77 (d, Jp-m = 8.8 Hz, 2 H, 2x m-CH-Bz), 7.69-
7.19 (m, 14 H, CH-Bz, H-4Bf, H-6Bf, H7-Bf, H-m-Phe-O, H-o-Phe-O), 
6.16 (dd, J4’-3’ = 9.9 Hz, J2’-3’ = 3.4 Hz, 1 H, H3’), 5.90 (m, 1 H, H2’), 5.86 
(m, 1 H, H4’), 5.82 (br d, J1’-2’ = 2.1 Hz, 1 H, H1’), 4.28 (dd, J5’eq-5’ax = 11.2 
Hz, J5’eq-4’ = 5.5 Hz, 1 H, H5’eq), 4.02 (br t, J5’ax-4’ = 10.7 Hz, 1 H, H5’ax), 
2.43 (s, 3 H, CH3 Bf) ppm. 13C-NMR (100 MHz, CDCl3): δ = 165.9 (C=O 
Bz), 165.7 (2x C=O Bz), 155.9 (Cq Bf), 152.2 (Cq Bf), 152.0 (Cq Bf), 133.9 
(p-CH-Bz), 133.7 (p-CH-Bz), 133.5 (p-CH-Bz), 132.8 (Cq), 130.1 (2x o-
CH-Bz), 130.0 (2x o-CH-Bz), 129.9 (2x o-CH-Bz), 129.3 (Cq Bz), 129.2 
(Cq Bz), 129.2 (Cq Bz), 128.8 (C-m-Ph-O), 128.6 (2x m-CH-Bz), 128.6 (2x 
m-CH-Bz), 128.4 (2x m-CH-Bz), 128.1 (Cq Bf), 125.9 (Cq Bf), 124.3 (C6-
Bf), 119.0 (C4-Bf), 116.9 (C-o-Ph-O), 112.0 (C7-Bf), 110.2 (Cq Bf), 96.1 
(C1’), 70.4 (C2’), 69.2 (C3’), 67.7 (C4’), 60.8 (C5’), 9.5 (CH3 Bf) ppm. ESI-
MS: Calculated forC41H31ClNaO9 [M+Na]+ 725.2 Found 725.1 Calctd for 
[2M+Na]+ 1427.3 Found 1426.7. β anomer (55) [α]D25 = +66 (c=0.3, 
DCM) 1H-NMR (400 MHz, CDCl3): δ = 8.27 (bd, Jo-m = 7.7 Hz, 2 H, 2x o-
CH-Bz), 8.15 (bd, Jo-m = 7.4 Hz, 2 H, 2x o-CH-Bz), 7.95 (bd, Jo-m = 7.2 Hz, 
2 H, 2x o-CH-Bz), 7.74 (bd, 2 H, 2x m-CH-Bz), 7.69-7.19 (m, 14 H, CH-
Bz, H-4Bf, H-6Bf, H7-Bf, H-m-Phe-O, H-o-Phe-O), 5.95 (m, 2 H, H1’, H3’), 
5.82 (bt, J = 3.7 Hz, 1 H, H2’), 5.46 (m, 1 H, H4’), 4.58 (bdd, J5’eq-5’ax = 
13.2 Hz, J5’eq-4’ = 1.7 Hz, 1 H, H5’eq), 4.01 (bdd, J5’ax-4’ = 2.0 Hz, 1 H, H5’ax), 
2.41 (s, 3 H, CH3 Bf) ppm. 13C-NMR (100 MHz, CDCl3): δ = 165.6 (C=O 
Bz), 165.3 (2x C=O Bz), 157.2 (Cq Bf), 152.1 (Cq Bf), 151.9 (Cq Bf), 133.7 
(p-CH-Bz), 133.6 (p-CH-Bz), 133.5 (p-CH-Bz), 132.6 (Cq), 130.1 (2x o-
CH-Bz), 130.0 (2x o-CH-Bz), 129.9 (2x o-CH-Bz), 129.6 (Cq Bz), 129.2 
(Cq Bz), 129.1 (Cq Bz), 128.6 (2x m-CH-Bz), 128.6 (2x m-CH-Bz), 128.5 
(2x m-CH-Bz), 128.4 (C-m-Ph-O), 128.0 (Cq Bf), 125.6 (Cq Bf), 124.2 
(C6-Bf), 118.9 (C4-Bf), 116.9 (C-o-Ph-O), 111.8 (C7-Bf), 110.0 (Cq Bf), 
95.0 (C1’), 69.4 (C4’), 67.3 (C3’), 67.2 (C2’), 59.1 (C5’), 9.4 (CH3 Bf) ppm. 
4-[5-chloro-3-methylbenzofuran-2-yl]-phenoxy--L-lyxopyranoside 
(46): 1 M MeONa in MeOH (85 μL) was added to a solution of 4-[5-
chloro-3-methylbenzofuran-2-yl]-phenoxy-2,3,4-tribenzoyl--L-
lyxopyranoside (30 mg, 0.043 mmol) in MeOH (350 μL). The reaction 
was stirred under nitrogen atmosphere at room temperature for 1 h (TLC 
7:3 Hex:EtOAc) and then quenched with Amberlite IR-120 H+. The resin 
was filtered off, the solvent was evaporated in vacuo and the crude 
product (16.8 mg, quantitative yield) was used without further 
purifications. 1H-NMR (400 MHz, CD3OD): δ = 7.71 (d, Jo-m = 8.9 Hz, 2 H, 
2 x H-m-Phe-O), 7.46 (bd, J4-6 = 2 Hz, 1 H, H4-Bf), 7.36 (d, J7-6 = 8.8 Hz, 
1 H, H7-Bf), 7.21-7.14 (m, 3 H, H6-Bf, 2 x H-o-Phe-O), 5.48 (d, J1’-2’ = 2.9 
Hz, 1 H, H1’), 4.03 (m, 1 H, H2’), 3.93-3.86 (m, 2 H, H3’, H4’), 3.78 (bdd, 
J5’eq-5’ax = 11.4 Hz, J5’eq-4’ = 3.9 Hz, 1 H, H5’eq), 3.59-3.50 (m, 1 H, H5’ax), 
2.39 (s, 3 H, CH3 Bf) ppm. 13C-NMR (100 MHz, CD3OD): δ = 157.3 (Cq), 
152.9 (Cq), 133.4 (Cq), 128.8 (C-m-Ph-O), 128.7 (Cq), 125.7 (Cq), 124.7 
(C6-Bf), 119.3 (C4-Bf), 117.3 (C-o-Ph-O), 112.3 (C7-Bf), 110.4 (Cq), 99.3 
(C1’), 72.0 (C4’), 70.7 (C2’), 67.8 (C3’), 64.3 (C5’), 9.5 (CH3 Bf) ppm. ESI-
MS: Calculated for C20H19ClNaO6 [M+Na]+ 413.1 Found 413.0 HR-MS 
Calculated for C20H19ClNaO6 [M+Na]+ 413.07624 Found 413.07817 
4-[5-chloro-3-methylbenzofuran-2-yl]-phenoxy--L-lyxopyranoside 
(47): 1 M MeONa in MeOH (43 μL) was added to a solution of 4-[5-
chloro-3-methylbenzofuran-2-yl]-phenoxy-2,3,4-tribenzoyl--L-
lyxopyranoside (15 mg, 0.021 mmol) in MeOH (160 μL). The reaction 
was stirred under nitrogen atmosphere at room temperature for 1 h (TLC 
7:3 Hex:EtOAc) and then quenched with Amberlite IR-120 H+. The resin 
was filtered off, the solvent was evaporated in vacuo and the crude 
product (10.4 mg, quantitative yield) was used without further 
purifications. 1H-NMR (400 MHz, CD3OD/CDCl3): δ = 7.74-7.70 (m, 2 H, 
2 x H-m-Phe-O), 7.47 (d, J4-6 = 2.0 Hz, 1 H, H4-Bf), 7.37 (d, J7-6 = 8.7 Hz, 
1 H, H7-Bf), 7.23-7.18 (m, 3 H, H6-Bf, 2 x H-o-Phe-O), 5.37 (d, J1’-2’ = 2.6 
Hz, 1 H, H1’), 4.12-4.07 (m, 2 H, H2’, H5’eq), 3.89-3.84 (m, 1 H, H4’), 3.79 
(dd, J3’-2’ = 6.2 Hz, J3’-4’ = 3.5 Hz, 1 H, H3’), 3.43 (dd, J5’eq-5’ax = 11.9 Hz, 
J5’ax-4’ = 5.5 Hz, 1 H, H5’ax), 2.40 (s, 3 H, CH3 Bf) ppm. 13C-NMR (100 MHz, 
CD3OD/CDCl3): δ = 158.2 (Cq), 153.0, 153.0 (Cq), 133.6 (Cq), 128.9 (C-
m-Ph-O), 128.8 (Cq), 126.0 (Cq), 124.8 (C6-Bf), 119.5 (C4-Bf), 117.7 (C-
o-Ph-O), 112.5 (C7-Bf), 110.6 (Cq), 99.2 (C1’), 72.8(C3’), 69.2 (C4’), 68.3 
(C2’), 63.2 (C5’), 9.4 (CH3 Bf) ppm. HRMS: Calculated for C20H19ClNaO6 
[M+Na]+ 413.07624 Found 413.07813 
4-[5-chloro-3-methylbenzofuran-2-yl]-phenoxy--D-lyxopyranoside 
(48) and 4-[5-chloro-3-methylbenzofuran-2-yl]-phenoxy--D-
lyxopyranoside (49): Synthesized as described above for the L-
enantiomer with similar yields and identical spectral data.  
Supporting Information (see footnote on the first page of this article): 
Procedures for the synthesis of 2a-d and 58a-d; NMR spectra of all new 
compounds; STD-NMR quantitative analysis; configurational assignment 
of 42-49. 
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Hsp90. ATP-regulated internal dynamics can be modulated in an allosteric fashion, targeting the protein C-terminal domain 
(CTD) with a family of 2-phenyl-benzofuran derivatives. Here we report 28 new derivatives that explore the chemical space at 
opposite ends of the benzofuran scaffold. Interaction of the compounds with the full-length protein was explored by STD-NMR.  
 
 
